Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,8.300000190734863,8.75,8.289999961853027,8.40999984741211,373114,0.0,0.0,,,,,,,,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-06-28,8.5,8.520000457763672,8.130000114440918,8.239999771118164,53256,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-06-29,8.25,8.489999771118164,7.920000076293945,7.96999979019165,120490,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-06-30,8.170000076293945,8.170000076293945,7.829999923706055,7.920000076293945,158041,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-01,8.0,8.460000038146973,7.730000019073486,7.849999904632568,277995,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-04,8.0,8.069999694824219,7.510000228881836,7.619999885559082,206571,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-05,7.619999885559082,7.829999923706055,7.480000019073486,7.71999979019165,165876,0.0,0.0,,,,,,,13.660095573673729,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-06,7.929999828338623,7.929999828338623,7.460000038146973,7.610000133514404,187615,0.0,0.0,,,,,,,11.757505013076567,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-07,7.610000133514404,7.960000038146973,7.440000057220459,7.659999847412109,262980,0.0,0.0,,,,,,,17.389809152236523,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-08,7.570000171661377,7.650000095367432,7.460000038146973,7.53000020980835,255319,0.0,0.0,7.852999925613403,,,-4.113074224686485,,,14.753158281898408,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-11,7.53000020980835,8.039999961853027,7.380000114440918,7.5,377540,0.0,0.0,7.761999940872192,,,-3.375417970471563,,,14.217428609758585,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-12,7.5,7.559999942779541,7.099999904632568,7.349999904632568,319941,0.0,0.0,7.6729999542236325,,,-4.209566682106749,,,11.892158922531351,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-13,7.360000133514404,7.440000057220459,7.210000038146973,7.320000171661377,177638,0.0,0.0,7.607999992370606,,,-3.785486606178212,,,11.487500706793412,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-14,7.599999904632568,7.599999904632568,7.179999828338623,7.289999961853027,229514,0.0,0.0,7.544999980926514,,,-3.379721931320311,,,11.081417922347555,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-15,7.360000133514404,7.360000133514404,6.989999771118164,7.119999885559082,190958,0.0,0.0,7.471999979019165,,,-4.710922034909976,,,9.115076780301692,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-18,7.199999809265137,7.829999923706055,7.199999809265137,7.829999923706055,240169,0.0,0.0,7.4929999828338625,,,4.497530250156738,,,49.455031242143235,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-19,7.980000019073486,7.989999771118164,7.710000038146973,7.900000095367432,106324,0.0,0.0,7.51100001335144,,,5.1790717790508705,,,51.7298541167439,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-20,8.0,8.100000381469727,7.900000095367432,8.079999923706055,56320,0.0,0.0,7.557999992370606,,,6.906588143191052,,,57.07913923505129,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-21,8.079999923706055,8.079999923706055,7.75,7.760000228881836,140099,0.0,0.0,7.568000030517578,,,2.537000496696968,,,47.08848346550744,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-22,8.0,8.0600004196167,7.539999961853027,7.699999809265137,206709,0.0,0.0,7.584999990463257,,,1.5161479096436499,,,45.48103761690625,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-25,7.699999809265137,7.900000095367432,7.5,7.699999809265137,216757,0.0,0.0,7.604999971389771,,,1.2491760451381744,,,45.48103761690624,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-26,7.699999809265137,7.789999961853027,7.5,7.510000228881836,557670,0.0,0.0,7.621000003814697,,,-1.4564988174425992,,,40.41434131468663,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-27,7.690000057220459,7.989999771118164,7.190000057220459,7.53000020980835,404673,0.0,0.0,7.642000007629394,,,-1.4655822783202,,,41.15744202454998,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-28,7.579999923706055,7.769999980926514,7.349999904632568,7.630000114440918,215363,0.0,0.0,7.676000022888184,,,-0.5992692588601372,,,44.860203833111456,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-07-29,7.699999809265137,8.319999694824219,7.630000114440918,7.989999771118164,369800,0.0,0.0,7.763000011444092,,,2.9241241702876826,,,55.6740356060986,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-01,8.0600004196167,8.649999618530273,8.0600004196167,8.619999885559082,332104,0.0,0.0,7.8420000076293945,,,9.92093696981357,,,67.63594701024377,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-02,8.65999984741211,8.859999656677246,8.199999809265137,8.369999885559082,228260,0.0,0.0,7.888999986648559,,,6.0970959529036985,,,60.6423229847917,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-03,8.5,8.800000190734863,1.0800000429153442,1.2979999780654907,27390043,0.0,0.0,7.210799992084503,,,-81.99922367157123,,,14.612580541744677,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-04,1.3200000524520874,1.684000015258789,1.2680000066757202,1.399999976158142,54549034,0.0,0.0,6.574799966812134,,,-78.7065768810462,,,15.607548101735475,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-05,1.4279999732971191,1.4279999732971191,1.281999945640564,1.2999999523162842,8782398,0.0,0.0,5.934799981117249,,,-78.09530301859382,,,15.417867048650464,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-08,1.3020000457763672,1.3480000495910645,1.1799999475479126,1.25,7359748,0.0,0.0,5.289800000190735,,,-76.36961699960436,,,15.317628453574898,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-09,1.25,1.25,1.1799999475479126,1.2300000190734863,2234509,0.0,0.0,4.6617999792099,,,-73.61534118669006,,,15.274849290547579,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-10,1.2280000448226929,1.2760000228881836,1.190000057220459,1.25,3295375,0.0,0.0,4.033799958229065,,,-69.01184954772076,,,15.528907683081457,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-11,1.2480000257492065,1.2960000038146973,1.2120000123977661,1.2699999809265137,1909450,0.0,0.0,3.3977999448776246,,,-62.62287357909019,,,15.800810552014937,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-12,1.2719999551773071,1.350000023841858,1.2519999742507935,1.2999999523162842,2012240,0.0,0.0,2.7287999629974364,,,-52.36001282819185,,,16.23635969688675,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-15,1.3359999656677246,1.3359999656677246,1.2480000257492065,1.2599999904632568,1122605,0.0,0.0,1.992799973487854,,,-36.77238020743398,,,16.11665051490604,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-16,1.2619999647140503,1.3359999656677246,1.2599999904632568,1.3140000104904175,1400308,0.0,0.0,1.2871999859809875,,,2.0820404600148765,,,17.006267615010387,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-17,1.315999984741211,1.3359999656677246,1.25600004196167,1.2640000581741333,854545,0.0,0.0,1.2837999939918519,,,-1.5422913156552187,,,16.828305280909206,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-18,1.2640000581741333,1.315999984741211,1.2400000095367432,1.2760000228881836,1760633,0.0,0.0,1.2713999986648559,,,0.36180778890658966,,,17.052650417902015,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-19,1.281999945640564,1.2899999618530273,1.1699999570846558,1.2000000476837158,2259499,0.0,0.0,1.261400008201599,5.658549976348877,,-4.867604258654022,-77.70806985051134,,16.744591468270016,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-22,1.2039999961853027,1.2719999551773071,1.2000000476837158,1.2100000381469727,1164693,0.0,0.0,1.2574000120162965,5.478549981117249,,-3.7696813596586396,-77.04867133912919,,16.95716780189109,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-23,1.2339999675750732,1.246000051498413,1.159999966621399,1.215999960899353,1377153,0.0,0.0,1.256000006198883,5.302949985861778,,-3.184716966728747,-76.31506973387432,,17.093946811052987,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-24,1.2120000123977661,1.215999960899353,1.1019999980926514,1.1519999504089355,3382098,0.0,0.0,1.2462000012397767,5.132499989867211,,-7.5589833684100975,-75.71943490111885,,16.776523842534715,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-25,1.1519999504089355,1.1640000343322754,1.0700000524520874,1.1640000343322754,1769871,0.0,0.0,1.2356000065803527,4.963599988818169,,-5.794753307442711,-75.10677715037733,,17.08741286604055,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-26,1.1759999990463257,1.1959999799728394,1.1119999885559082,1.1579999923706055,768824,0.0,0.0,1.221400010585785,4.79629999101162,,-5.190766142598342,-74.53453677053734,,17.053110992354718,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-29,1.1480000019073486,1.1480000019073486,1.062000036239624,1.065999984741211,1342999,0.0,0.0,1.2020000100135804,4.632449993491173,,-11.314477881812405,-74.05260689910412,,16.505968064670412,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-30,1.0880000591278076,1.1720000505447388,1.0740000009536743,1.1360000371932983,1520175,0.0,0.0,1.1842000126838683,4.467849999666214,,-4.070256288997132,-73.49508124103679,,18.644804864514924,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-08-31,1.149999976158142,1.190000057220459,1.1239999532699585,1.187999963760376,992385,0.0,0.0,1.1766000032424926,4.307299995422364,,0.9688900634427334,-72.68358357920417,,20.278557903696722,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-01,0.7139999866485596,0.8999999761581421,0.6510000228881836,0.8190000057220459,12541287,0.0,0.0,1.130900001525879,4.136274999380111,,-27.579803287912164,-72.6589745194562,,17.580557393272173,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-02,0.8149999976158142,0.8149999976158142,0.7250000238418579,0.75,4052301,0.0,0.0,1.0858999967575074,3.966774994134903,,-30.93286654024342,-72.62511742251398,,17.12182181231303,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-05,0.6990000009536743,0.7289999723434448,0.6600000262260437,0.6790000200271606,5458823,0.0,0.0,1.0327999949455262,3.796249994635582,,-34.25638813418336,-72.79420490207549,,16.640656807942506,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-06,0.6800000071525574,0.6800000071525574,0.5360000133514404,0.578000009059906,8957311,0.0,0.0,0.9689999997615815,3.6269499972462653,,-40.350876243331214,-73.28333722556728,,15.953815353031374,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-07,0.578000009059906,0.6179999709129333,0.5109999775886536,0.5249999761581421,7242648,0.0,0.0,0.9063000023365021,3.4570749923586845,,-42.07216431593766,-73.78419605187234,,15.590171435234922,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-08,0.5270000100135803,0.5630000233650208,0.5249999761581421,0.5600000023841858,4059671,0.0,0.0,0.8458999991416931,3.2888249933719633,,-33.79832096555156,-74.27956790505871,,16.93664597030036,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-09,0.5740000009536743,0.6359999775886536,0.550000011920929,0.6039999723434448,3843027,0.0,0.0,0.790499997138977,3.1259249955415727,,-23.5926660936779,-74.71148545577879,,18.692563396263623,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-12,0.6039999723434448,0.6349999904632568,0.6000000238418579,0.6029999852180481,1880671,0.0,0.0,0.7441999971866607,2.9452499970793724,,-18.97339592883615,-74.73219597913116,,18.682896978595323,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-13,0.6399999856948853,0.7300000190734863,0.6389999985694885,0.6869999766349792,7624288,0.0,0.0,0.6992999911308289,2.764924994111061,,-1.758903854118376,-74.70817499135605,,22.316959749287903,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-14,0.6489999890327454,0.6859999895095825,0.6349999904632568,0.6620000004768372,2669412,0.0,0.0,0.646699994802475,2.5794749960303305,,2.365858326477232,-74.92900703446591,,22.001812141569772,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-15,0.6620000004768372,0.6759999990463257,0.6100000143051147,0.6600000262260437,2037957,0.0,0.0,0.6307999968528748,2.401974990963936,,4.629047165321943,-73.7382779077259,,21.975077221646856,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-16,0.6790000200271606,0.6790000200271606,0.6499999761581421,0.652999997138977,990033,0.0,0.0,0.6210999965667725,2.2257999956607817,,5.136049065937336,-72.09542646340135,,21.874886761163367,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-19,0.652999997138977,0.6690000295639038,0.6499999761581421,0.6539999842643738,1708951,0.0,0.0,0.6185999929904937,2.0496500000357627,,5.722598072260899,-69.81923777329298,,21.92964649845645,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-20,0.6549999713897705,0.718999981880188,0.6539999842643738,0.6859999895095825,2345597,0.0,0.0,0.6293999910354614,1.8790499940514565,,8.992691337825612,-66.5043509737386,,23.770975454718425,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-21,0.699999988079071,0.7089999914169312,0.6579999923706055,0.6769999861717224,583079,0.0,0.0,0.6445999920368195,1.7077249884605408,,5.026372096674216,-62.25387598164118,,23.602367480983645,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-22,0.6769999861717224,0.6769999861717224,0.6489999890327454,0.6499999761581421,892110,0.0,0.0,0.653599989414215,1.5332249850034714,,-0.5507976307189728,-57.37090147844576,,23.073614681727975,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-23,0.6520000100135803,0.75,0.6499999761581421,0.7070000171661377,2723628,0.0,0.0,0.6638999938964844,1.3511499911546707,,6.491945122140417,-50.86407887779163,,26.801766898755943,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-26,0.75,0.8429999947547913,0.7110000252723694,0.8069999814033508,3607144,0.0,0.0,0.6842999935150147,1.1558249935507774,,17.93073053501993,-40.79553588707267,,32.94191461618493,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-27,0.8059999942779541,0.8059999942779541,0.7200000286102295,0.7620000243186951,927547,0.0,0.0,0.6917999982833862,0.9656249970197678,,10.147445245663672,-28.357281510057668,,31.655091844404083,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-28,0.7699999809265137,0.7720000147819519,0.6840000152587891,0.7250000238418579,963830,0.0,0.0,0.6981000006198883,0.951299998164177,,3.853319466850498,-26.61620919088775,,30.596765205740923,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-29,0.7400000095367432,0.7400000095367432,0.7099999785423279,0.7300000190734863,708436,0.0,0.0,0.7050999999046326,0.9345499992370605,,3.5314167029104495,-24.55192333419766,,30.9328125477778,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-09-30,0.7300000190734863,0.7300000190734863,0.6809999942779541,0.699999988079071,507468,0.0,0.0,0.709799998998642,0.9195500001311302,,-1.3806721517887315,-22.81007026290874,,29.994391784330844,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-03,0.699999988079071,0.7059999704360962,0.6399999856948853,0.6840000152587891,666659,0.0,0.0,0.7128000020980835,0.9054000005126,,-4.040402182172195,-21.272365618011303,,29.480705121181686,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-04,0.6840000152587891,0.6940000057220459,0.6499999761581421,0.6830000281333923,648646,0.0,0.0,0.7125000059604645,0.8917250007390976,,-4.140347730566763,-20.098684530554173,,29.44676169951525,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-05,0.6899999976158142,0.7099999785423279,0.6779999732971191,0.6809999942779541,361760,0.0,0.0,0.7129000067710877,0.8775000005960465,,-4.474682590847087,-18.757834041385006,,29.37391544701356,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-06,0.6809999942779541,0.7089999914169312,0.6600000262260437,0.6880000233650208,399540,0.0,0.0,0.7167000114917755,0.8629500016570091,,-4.004463187745341,-16.947678299369485,,30.026371476579797,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-07,0.6650000214576721,0.699999988079071,0.6650000214576721,0.6990000009536743,450072,0.0,0.0,0.7159000098705292,0.8479250028729439,,-2.360666110328901,-15.570362066820415,,31.103481419817072,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-10,0.6990000009536743,0.699999988079071,0.6510000228881836,0.6790000200271606,366809,0.0,0.0,0.7031000137329102,0.8334000036120415,,-3.42767646636749,-15.634747937892692,,30.193440933563195,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-11,0.6790000200271606,0.6790000200271606,0.6399999856948853,0.6669999957084656,286377,0.0,0.0,0.6936000108718872,0.8172250032424927,,-3.8350655632176447,-15.127411897592498,,29.633209299714068,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-12,0.6669999957084656,0.6669999957084656,0.6399999856948853,0.6639999747276306,364570,0.0,0.0,0.6875000059604645,0.8022250011563301,,-3.4181863315045904,-14.300850139362476,,29.48591144400129,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-13,0.6639999747276306,0.6769999861717224,0.640999972820282,0.675000011920929,280345,0.0,0.0,0.6820000052452088,0.7872000008821487,,-1.0263919751383292,-13.363820568985158,,30.84330723218524,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-14,0.675000011920929,0.675000011920929,0.6489999890327454,0.6639999747276306,150851,0.0,0.0,0.6784000039100647,0.7737999990582466,,-2.122645798855731,-12.328766511280492,,30.21688809052627,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-17,0.6600000262260437,0.699999988079071,0.6399999856948853,0.675000011920929,420390,0.0,0.0,0.6775000035762787,0.7604249984025955,,-0.36900245640637597,-10.905085314201282,,31.71051658767695,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-18,0.675000011920929,0.7009999752044678,0.6549999713897705,0.6890000104904175,147291,0.0,0.0,0.6781000018119812,0.7472499996423722,,1.607433807596214,-9.253930794712028,,33.65680484907401,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-19,0.6890000104904175,0.7170000076293945,0.6700000166893005,0.699999988079071,430081,0.0,0.0,0.6800000011920929,0.7359500005841255,,2.9411745370465576,-7.6024185539268885,,35.219049843696695,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-20,0.7170000076293945,0.7170000076293945,0.6610000133514404,0.6859999895095825,300483,0.0,0.0,0.6797999978065491,0.7239999994635582,,0.9120317333095606,-6.104972609082697,,34.11787665841423,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-21,0.6970000267028809,0.6970000267028809,0.6669999957084656,0.6830000281333923,440767,0.0,0.0,0.6782000005245209,0.7121250003576278,,0.7077598945973296,-4.76391080443319,,33.87347167491512,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-24,0.6660000085830688,0.6819999814033508,0.6629999876022339,0.6790000200271606,139902,0.0,0.0,0.6782000005245209,0.7024500012397766,,0.11796217959613861,-3.4522030995026167,,33.52858754371654,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-25,0.6800000071525574,0.6800000071525574,0.6520000100135803,0.6539999842643738,301986,0.0,0.0,0.6768999993801117,0.6903999999165535,,-3.3830721135631827,-1.9553882587012672,,31.378249880919185,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-26,0.6600000262260437,0.675000011920929,0.652999997138977,0.6700000166893005,332704,0.0,0.0,0.6775000035762787,0.6774500012397766,,-1.1070091287658215,0.007380963378934229,,34.28316187193906,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-27,0.6700000166893005,0.6700000166893005,0.6549999713897705,0.6690000295639038,331272,0.0,0.0,0.6769000053405761,0.673700001835823,,-1.1670816537662072,0.4749893863786805,,34.18575835529418,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-28,0.6690000295639038,0.6850000023841858,0.6499999761581421,0.6600000262260437,185128,0.0,0.0,0.6765000104904175,0.6714500024914741,,-2.4390220263873217,0.7521048447695134,,33.26959231027888,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-10-31,0.652999997138977,0.6880000233650208,0.6499999761581421,0.6669999957084656,232649,0.0,0.0,0.6757000088691711,0.6711500018835068,,-1.287555578882649,0.6779418867459199,,34.734633760694834,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-01,0.6669999957084656,0.6679999828338623,0.6399999856948853,0.6600000262260437,256346,0.0,0.0,0.6728000104427337,0.6732000023126602,,-1.9024946519051116,-0.0594164985966059,,33.93235585807135,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-02,0.6600000262260437,0.6650000214576721,0.6399999856948853,0.6650000214576721,260580,0.0,0.0,0.6693000137805939,0.6767000034451485,,-0.642461113758676,-1.093540657142083,,35.08570442922401,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-03,0.675000011920929,0.675000011920929,0.6579999923706055,0.6700000166893005,101612,0.0,0.0,0.6677000164985657,0.6794500038027763,,0.3444660976340985,-1.7293380290599398,,36.28356944871782,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-04,0.6740000247955322,0.7110000252723694,0.6399999856948853,0.6800000071525574,317996,0.0,0.0,0.6674000144004821,0.6813500046730041,,1.887922157657379,-2.0474044436554895,,38.71917425154197,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-07,0.6790000200271606,0.699999988079071,0.656000018119812,0.6949999928474426,617941,0.0,0.0,0.6690000116825103,0.6836500048637391,,3.8863947250977326,-2.1429083708042502,,42.283143866610665,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-08,0.6949999928474426,0.6949999928474426,0.6660000085830688,0.6899999976158142,184273,0.0,0.0,0.6726000130176544,0.6837250053882599,,2.586973574397347,-1.627115036444814,,41.418441659401886,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-09,0.6650000214576721,0.6970000267028809,0.6650000214576721,0.6800000071525574,507731,0.0,0.0,0.6736000120639801,0.6841750055551529,,0.9501180186988123,-1.545656214464016,,39.67105997070191,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-10,0.6740000247955322,0.75,0.6660000085830688,0.7009999752044678,982862,0.0,0.0,0.6768000066280365,0.6852000042796135,,3.57564544022402,-1.225919089187442,,44.92574167525462,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-11,0.703000009059906,0.7699999809265137,0.675000011920929,0.6919999718666077,1126871,0.0,0.0,0.6800000011920929,0.6861750036478043,,1.7647015666879213,-0.8999165552350564,,43.18950984215053,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-14,0.699999988079071,0.718999981880188,0.6100000143051147,0.6520000100135803,1532415,0.0,0.0,0.6785000026226043,0.6861250042915344,,-3.905673177095604,-1.111313772452204,,36.44759941449686,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-15,0.6299999952316284,0.6489999890327454,0.6100000143051147,0.6449999809265137,536245,0.0,0.0,0.6769999980926513,0.6851000040769577,,-4.726738147162929,-1.1823100184066706,,35.40598650614386,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-16,0.6449999809265137,0.6449999809265137,0.609000027179718,0.6230000257492065,460784,0.0,0.0,0.6727999985218048,0.6837500050663948,,-7.401898466410939,-1.6014634681467692,,32.28334199691264,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-17,0.6230000257492065,0.6230000257492065,0.5950000286102295,0.6079999804496765,803961,0.0,0.0,0.6665999948978424,0.6827000051736831,,-8.790881322635839,-2.35828477425378,,30.319853324060205,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-18,0.5989999771118164,0.6439999938011169,0.5950000286102295,0.6309999823570251,749401,0.0,0.0,0.6616999924182891,0.6808000043034553,,-4.63956633112022,-2.805524642249073,,36.6792504364642,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-21,0.6309999823570251,0.6309999823570251,0.6100000143051147,0.6129999756813049,414364,0.0,0.0,0.6534999907016754,0.6759500041604042,,-6.197401009429984,-3.3212535425033205,,34.059417583621794,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-22,0.6100000143051147,0.6100000143051147,0.5920000076293945,0.6000000238418579,372111,0.0,0.0,0.6444999933242798,0.6719000041484833,,-6.9045725280607915,-4.077989381608693,,32.26689721953025,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-23,0.6000000238418579,0.6200000047683716,0.5899999737739563,0.6000000238418579,315629,0.0,0.0,0.6364999949932099,0.6687750041484832,,-5.7344809801202485,-4.825989152565215,,32.266897219530264,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-24,0.6000000238418579,0.6169999837875366,0.5899999737739563,0.6129999756813049,272298,0.0,0.0,0.6276999950408936,0.6658500030636787,,-2.3418861678708414,-5.7295198388902975,,36.16332394189887,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-25,0.5989999771118164,0.6100000143051147,0.5299999713897705,0.6100000143051147,2250884,0.0,0.0,0.6194999992847443,0.6636000037193298,,-1.5334923310085475,-6.645570251268057,,35.653608677782216,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-28,0.6000000238418579,0.6100000143051147,0.5699999928474426,0.6079999804496765,1364676,0.0,0.0,0.6150999963283539,0.661700002849102,,-1.1542864446526877,-7.042467329620834,,35.296421107861235,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-29,0.609000027179718,0.6690000295639038,0.6029999852180481,0.6159999966621399,686081,0.0,0.0,0.6121999979019165,0.6600250020623207,,0.6207119851758358,-7.245938261576419,,37.973187734533816,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-11-30,0.6159999966621399,0.6159999966621399,0.5799999833106995,0.5920000076293945,649992,0.0,0.0,0.6090999960899353,0.6578000023961067,,-2.807418908276576,-7.403467030826462,,33.4962299911537,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-01,0.6069999933242798,0.6069999933242798,0.5699999928474426,0.5989999771118164,611661,0.0,0.0,0.6081999957561492,0.6555750012397766,,-1.5126633851575169,-7.22648139328607,,35.87104554637496,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-02,0.5899999737739563,0.6499999761581421,0.5899999737739563,0.6169999837875366,3455360,0.0,0.0,0.6067999958992004,0.6535250008106231,,1.6809472572953992,-7.149688971877999,,41.641970678824535,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-05,0.6209999918937683,0.7120000123977661,0.6209999918937683,0.6800000071525574,1241148,0.0,0.0,0.6134999990463257,0.6535500004887581,,10.839447140929863,-6.128069988903831,,56.42291507993109,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-06,0.6800000071525574,0.7400000095367432,0.6549999713897705,0.7379999756813049,1132969,0.0,0.0,0.6272999942302704,0.655324999988079,,17.647056028889203,-4.276504903417151,,65.16941127365557,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-07,0.7379999756813049,0.7400000095367432,0.699999988079071,0.7200000286102295,1033206,0.0,0.0,0.6392999947071075,0.656725001335144,,12.62318701255337,-2.6533186025521873,,61.07255985157954,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-08,0.7200000286102295,0.7329999804496765,0.7099999785423279,0.7269999980926514,162609,0.0,0.0,0.6506999969482422,0.6580250009894371,,11.725833948402215,-1.1131802029072804,,62.07114645156062,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-09,0.7300000190734863,0.75,0.7120000123977661,0.7379999756813049,217583,0.0,0.0,0.6634999930858612,0.659875001013279,2.364074992140134,11.228332083162961,0.5493452649389288,-72.08739133880387,63.64920857517222,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-12,0.7379999756813049,0.746999979019165,0.7009999752044678,0.7459999918937683,325831,0.0,0.0,0.6772999942302704,0.6616500005125999,2.3002083266774815,10.143215450868741,2.365297922700218,-71.23521409609384,64.79637266954077,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-13,0.7400000095367432,0.7760000228881836,0.7319999933242798,0.7549999952316284,936989,0.0,0.0,0.6911999940872192,0.6633000001311302,2.2378333285450935,9.230324318602149,4.2062406076546575,-70.35972287702192,66.09277674377765,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-14,0.7549999952316284,0.7590000033378601,0.7400000095367432,0.7400000095367432,401941,0.0,0.0,0.7059999942779541,0.664300000667572,2.1775833303729693,4.815866222996475,6.277283391310664,-69.49370472294197,61.99505132272761,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-15,0.746999979019165,0.7639999985694885,0.7200000286102295,0.722000002861023,108528,0.0,0.0,0.7182999968528747,0.665200001001358,2.117599996427695,0.515105947982635,7.982560999937265,-68.58707961260279,57.39630655256464,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-16,0.699999988079071,0.7329999804496765,0.6980000138282776,0.7099999785423279,185038,0.0,0.0,0.7275999963283539,0.6658749997615814,2.05809999704361,-2.4189139465145693,9.269757325154627,-67.64612989076878,54.49411527480748,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-19,0.7099999785423279,0.7390000224113464,0.6800000071525574,0.718999981880188,166708,0.0,0.0,0.731499993801117,0.6668749988079071,2.0005916645129522,-1.7088191424274337,9.690720916023578,-66.66611129911615,56.27966043985968,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-20,0.718999981880188,0.7379999756813049,0.6800000071525574,0.6949999928474426,138441,0.0,0.0,0.7271999955177307,0.6678999990224839,1.9420499995350837,-4.427943188773439,8.878574125173882,-65.6085065172176,50.580163052999296,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-21,0.6949999928474426,0.7120000123977661,0.6669999957084656,0.6669999957084656,116875,0.0,0.0,0.7218999922275543,0.667824998497963,1.8841916650533677,-7.604931030638296,8.097180227037622,-64.55641902656185,44.87088315399089,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-22,0.675000011920929,0.6859999895095825,0.6669999957084656,0.675000011920929,126986,0.0,0.0,0.7166999936103821,0.6679749980568885,1.8259833330909412,-5.818331528006454,7.294434027505896,-63.41834090423099,46.721311197712005,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-23,0.675000011920929,0.699999988079071,0.6570000052452087,0.6949999928474426,216341,0.0,0.0,0.7123999953269958,0.6688499972224236,1.7690249979496002,-2.442448426963632,6.511175642584309,-62.19103754906469,51.13696487278667,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-27,0.6899999976158142,0.7099999785423279,0.6650000214576721,0.7099999785423279,372869,0.0,0.0,0.7087999939918518,0.6699249967932701,1.712441664437453,0.16929804749545344,5.802887992635686,-60.8789595169454,54.2026514839471,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-28,0.699999988079071,0.7390000224113464,0.6850000023841858,0.699999988079071,257600,0.0,0.0,0.7032999932765961,0.6709249958395958,1.6570249984661738,-0.46921729405266893,4.825427229236892,-59.510267107579075,51.86636264587194,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-29,0.699999988079071,0.7329999804496765,0.6890000104904175,0.7099999785423279,479103,0.0,0.0,0.7002999901771545,0.6720499947667122,1.601941663523515,1.3851190205956714,4.203555632828871,-58.04778600435926,54.001540107906706,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2022-12-30,0.7250000238418579,0.7400000095367432,0.7099999785423279,0.7400000095367432,306897,0.0,0.0,0.7020999908447265,0.6737999945878983,1.547358330587546,5.398094172657304,4.200058843000843,-56.45481843032116,59.767470954914934,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-02,0.7400000095367432,0.7689999938011169,0.7110000252723694,0.7400000095367432,144580,0.0,0.0,0.7050999939441681,0.6752999946475029,1.4941916649540266,4.949654785465583,4.412853477397167,-54.80499520332416,59.767470954914934,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-03,0.7400000095367432,0.8600000143051147,0.7310000061988831,0.8199999928474426,763732,0.0,0.0,0.7151999950408936,0.6784249946475029,1.4357749988635382,14.653243642787888,5.420643502749816,-52.748515945430306,71.00716299720285,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-04,0.8199999928474426,0.8700000047683716,0.7900000214576721,0.8700000047683716,504053,0.0,0.0,0.7326999962329864,0.6829249948263169,1.3771916647752127,18.73891213884025,7.288501926822648,-50.41176821689631,75.5960031851984,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-05,0.8700000047683716,0.8889999985694885,0.8169999718666077,0.8880000114440918,214572,0.0,0.0,0.754799997806549,0.6881249949336052,1.3172583321730296,17.64706068158749,9.689373785844975,-47.7608166806254,77.00690531351906,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-09,0.8799999952316284,0.8799999952316284,0.8040000200271606,0.8399999737739563,670673,0.0,0.0,0.7712999939918518,0.6915999948978424,1.259591663380464,8.907037510340015,11.52400226749308,-45.09331754056376,66.04189486503424,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-10,0.8339999914169312,0.8339999914169312,0.800000011920929,0.8029999732971191,202508,0.0,0.0,0.7820999920368195,0.6943749949336052,1.202116664747397,2.672290176844262,12.633663041337243,-42.23730397419326,59.06080000399177,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-11,0.8029999732971191,0.8740000128746033,0.800000011920929,0.8640000224113464,825810,0.0,0.0,0.7974999964237213,0.6996749952435494,1.1451499998569488,8.33856128975992,13.981491670446228,-38.9010177416974,65.53009855674968,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-12,0.8640000224113464,0.9399999976158142,0.8320000171661377,0.9190000295639038,852532,0.0,0.0,0.8194000005722046,0.7065249964594841,1.0902249981959662,12.155239067872387,15.976080772563778,-35.194570145740926,70.11553402945177,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-13,0.9399999976158142,0.9399999976158142,0.8410000205039978,0.8999999761581421,1291366,0.0,0.0,0.838400000333786,0.7134499952197075,1.034974996248881,7.347325357804355,17.513491618371944,-31.065967989033062,66.80915032250854,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-16,0.9200000166893005,1.100000023841858,0.890999972820282,1.0579999685287476,1305703,0.0,0.0,0.8701999962329865,0.7246999949216842,0.9802083283662796,21.581242600405584,20.07727367612662,-26.066737656723742,76.66403742418991,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-17,1.0800000429153442,1.0800000429153442,0.9100000262260437,0.9399999976158142,2982728,0.0,0.0,0.8901999950408935,0.732424995303154,0.92145833025376,5.594248803903104,21.541454858792168,-20.51458310638401,61.88549315931548,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-18,0.9399999976158142,0.9800000190734863,0.9300000071525574,0.9700000286102295,1141812,0.0,0.0,0.9051999986171723,0.7413499966263771,0.8577083314458529,7.158642299165812,22.10157182658917,-13.56618917567568,63.796302617069436,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-19,0.9700000286102295,1.0579999685287476,0.7590000033378601,0.7900000214576721,15170992,0.0,0.0,0.8972000002861023,0.7460999965667725,0.7945416659116745,-11.948281185270378,20.251977538483608,-6.096806677761698,48.18675652717337,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-20,0.765999972820282,0.7950000166893005,0.7549999952316284,0.7900000214576721,7193952,0.0,0.0,0.8874000012874603,0.7508499965071678,0.7903083329399426,-10.97588231783616,18.18605652467217,-4.992777475341815,48.18675652717337,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-23,0.7839999794960022,0.8080000281333923,0.781000018119812,0.8009999990463257,4304223,0.0,0.0,0.8835000038146973,0.7555499970912933,0.7853166664640109,-9.337861280380357,16.93468429832364,-3.7904033676944358,49.06995332111859,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-24,0.800000011920929,0.8199999928474426,0.7950000166893005,0.8180000185966492,5020074,0.0,0.0,0.8850000083446503,0.7607499971985817,0.7813000003496806,-7.570620239125351,16.332568071457395,-2.630232067311082,50.47497715887795,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-25,0.8119999766349792,0.8149999976158142,0.8019999861717224,0.8119999766349792,1159635,0.0,0.0,0.8798000037670135,0.7658499971032142,0.7776500001549721,-7.70629993654659,14.878893659960694,-1.5173925351258721,49.95120174383039,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-26,0.8119999766349792,0.8500000238418579,0.8069999814033508,0.8360000252723694,1572891,0.0,0.0,0.8715000033378602,0.77134999781847,0.7743666668732961,-4.073434071087233,12.983730576603888,-0.3895659748639091,52.092678600849204,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-27,0.8330000042915344,0.8330000042915344,0.8050000071525574,0.824999988079071,799460,0.0,0.0,0.864000004529953,0.777174997329712,0.7708250001072884,-4.513890769259813,11.171873451740238,0.8237923291979038,51.01525494196328,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-30,0.824999988079071,0.847000002861023,0.8109999895095825,0.8259999752044678,1417998,0.0,0.0,0.8408000051975251,0.7828499972820282,0.7671250000596046,-1.7602319102722168,7.402440840096203,2.0498611336094883,51.11424170281465,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-01-31,0.8259999752044678,0.8299999833106995,0.8050000071525574,0.8169999718666077,1913173,0.0,0.0,0.8285000026226044,0.7878499969840049,0.763100000222524,-1.38805440188214,5.159612336639347,3.2433490701433234,50.132341841696565,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-01,0.8180000185966492,0.8180000185966492,0.7839999794960022,0.7839999794960022,260163,0.0,0.0,0.8098999977111816,0.790449996292591,0.7591333334644635,-3.1979279279385304,2.46062388637054,4.125317839121538,46.597698520799725,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-02,0.7799999713897705,0.7929999828338623,0.7699999809265137,0.7710000276565552,333438,0.0,0.0,0.80799999833107,0.7912749975919724,0.7546083336075147,-4.5792043008587235,2.1136773928148225,4.859032474392035,45.244365456503246,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-03,0.7710000276565552,0.7960000038146973,0.7699999809265137,0.7699999809265137,319327,0.0,0.0,0.8059999942779541,0.7925249963998795,0.7504916662971178,-4.466502928910146,1.7002615613748546,5.600772398999668,45.135766841952325,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-06,0.7699999809265137,0.7940000295639038,0.7509999871253967,0.7900000214576721,604932,0.0,0.0,0.8048999965190887,0.794099996984005,0.7464416662851969,-1.8511585446457683,1.360030169512926,6.384736122246293,47.832600950899554,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-07,0.7900000214576721,0.7940000295639038,0.7680000066757202,0.7940000295639038,364713,0.0,0.0,0.8024999976158143,0.79549999833107,0.7430583328008652,-1.059186053229085,0.8799496290923956,7.0575435622305065,48.37911962376213,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-08,0.7820000052452087,0.7929999828338623,0.7720000147819519,0.7870000004768372,42729,0.0,0.0,0.8,0.7965249985456466,0.7395333324869474,-1.6249999403953608,0.4362702314049568,7.706436418091418,47.44242853333224,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-09,0.7870000004768372,0.7870000004768372,0.75,0.75,319932,0.0,0.0,0.791399997472763,0.796399998664856,0.7356499994794528,-5.2312354820531635,-0.627825364198312,8.258003021598594,42.73280299938169,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-10,0.75,0.7649999856948853,0.7400000095367432,0.75,597557,0.0,0.0,0.7838999986648559,0.7966499984264374,0.7322999998927117,-4.324531027247692,-1.6004518655326094,8.787382021460266,42.73280299938169,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-13,0.7509999871253967,0.7540000081062317,0.6840000152587891,0.6840000152587891,1419083,0.0,0.0,0.769700002670288,0.7956999987363815,0.7282999997337659,-11.134206458903936,-3.2675626627350782,9.254427986716196,35.45210573134263,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-14,0.6779999732971191,0.7049999833106995,0.5989999771118164,0.6909999847412109,1747065,0.0,0.0,0.7571000039577485,0.7952249988913536,0.7244083330035209,-8.730685361378807,-4.794239993304571,9.775793935750936,36.684246610308904,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-15,0.6800000071525574,0.7009999752044678,0.6700000166893005,0.6700000166893005,1096034,0.0,0.0,0.7457000076770782,0.7939999997615814,0.7211083332697551,-10.151534156958089,-6.083122430605351,10.108282366022626,34.55328881426148,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-16,0.6700000166893005,0.6740000247955322,0.6499999761581421,0.6710000038146973,110026,0.0,0.0,0.7357000052928925,0.7934000000357628,0.7172333329916001,-8.794345658926186,-7.272497446467041,10.619510212453383,34.74766888392641,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-17,0.6710000038146973,0.6710000038146973,0.6299999952316284,0.6399999856948853,327402,0.0,0.0,0.7227000057697296,0.7927249997854233,0.7126666665077209,-11.443201800830572,-8.833453471840583,11.23362955503617,31.613064570174075,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-20,0.6700000166893005,0.6729999780654907,0.6119999885559082,0.6200000047683716,181437,0.0,0.0,0.7057000041007996,0.7913499996066093,0.7110083331664403,-12.143970360553793,-10.82327611655873,11.29968000267612,29.748512062219177,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-21,0.6190000176429749,0.6399999856948853,0.6150000095367432,0.6309999823570251,815834,0.0,0.0,0.6893999993801116,0.7897499993443489,0.7100166663527488,-8.471136796576458,-12.70655271257333,11.229783295253958,32.11987250639122,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-22,0.6320000290870667,0.6539999842643738,0.6150000095367432,0.6269999742507935,243195,0.0,0.0,0.6733999967575073,0.7876749992370605,0.7095833326379458,-6.890410265835295,-14.5078874650382,11.005284792809501,31.700822045278784,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-23,0.625,0.652999997138977,0.6150000095367432,0.6150000095367432,105253,0.0,0.0,0.6598999977111817,0.7855499997735024,0.7098916659752528,-6.804059452973342,-15.995162892056438,10.657729541635032,30.418678546788087,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-24,0.6140000224113464,0.6480000019073486,0.6140000224113464,0.6460000276565552,389037,0.0,0.0,0.6495000004768372,0.783950001001358,0.7108999997377395,-0.5388718733968414,-17.150328509826473,10.275707032011198,37.456160744089495,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-27,0.6460000276565552,0.6769999861717224,0.621999979019165,0.6769999861717224,442585,0.0,0.0,0.6487999975681304,0.7823750004172325,0.7118749996026357,4.346484079730701,-17.07301521365942,9.90342417614743,43.59933340814663,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-02-28,0.6769999861717224,0.6779999732971191,0.6499999761581421,0.6779999732971191,432070,0.0,0.0,0.6474999964237214,0.780824999511242,0.7124916662772497,4.710421164765339,-17.07488914558006,9.590755438731255,43.7911256574553,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-01,0.6600000262260437,0.6779999732971191,0.6340000033378601,0.6499999761581421,254074,0.0,0.0,0.6454999923706055,0.7765749990940094,0.7128833328684171,0.6971315012739719,-16.878602437153198,8.934374432534026,39.71838582945363,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-02,0.6499999761581421,0.6759999990463257,0.6349999904632568,0.6499999761581421,99357,0.0,0.0,0.6433999896049499,0.7710749983787537,0.7125749995311101,1.0257983618004995,-16.558053242842863,8.209661984512204,39.718385829453624,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-03,0.6489999890327454,0.6499999761581421,0.6399999856948853,0.6480000019073486,37133,0.0,0.0,0.6441999912261963,0.7650749981403351,0.7124583328763644,0.5898805856732825,-15.799105605064758,7.385227014125113,39.414720788533074,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-06,0.6480000019073486,0.9430000185966492,0.6340000033378601,0.6399999856948853,14680604,0.0,0.0,0.6461999893188477,0.7600749984383584,0.712291665871938,-0.9594558536743094,-14.982075368019865,6.70839416714602,38.15799675711328,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-07,0.6710000038146973,0.6710000038146973,0.5600000023841858,0.5720000267028809,2115066,0.0,0.0,0.6402999937534333,0.7542999997735024,0.711616666118304,-10.666869860513128,-15.113350928582856,5.998079540214481,29.537110113690844,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-08,0.5910000205039978,0.6100000143051147,0.5640000104904175,0.6000000238418579,771018,0.0,0.0,0.6375999987125397,0.7476999998092652,0.7111666664481163,-5.897110248840141,-14.725157299025208,5.1370986696568055,35.95356772553082,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-09,0.6000000238418579,0.6200000047683716,0.5839999914169312,0.5899999737739563,291052,0.0,0.0,0.635099995136261,0.7394749984145165,0.7103666663169861,-7.101247316594374,-14.114744041656904,4.097648929453203,34.73694649922865,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-10,0.5899999737739563,0.5899999737739563,0.5400000214576721,0.5640000104904175,935824,0.0,0.0,0.6268999934196472,0.7310749992728234,0.7094249998529752,-10.033495547849597,-14.249564813021328,3.05176719517003,31.730550105422367,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-13,0.5640000104904175,0.5740000009536743,0.5320000052452087,0.5429999828338623,420833,0.0,0.0,0.6134999930858612,0.7181999996304512,0.7085333332419396,-11.491444343363217,-14.578112865283103,1.3643206233193304,29.509072322375857,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-14,0.5429999828338623,0.574999988079071,0.5220000147819519,0.5440000295639038,609312,0.0,0.0,0.6000999987125397,0.7083000004291534,0.7071750000119209,-9.348436805364658,-15.276013221947787,0.15908373701184986,29.761261350210475,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-15,0.5440000295639038,0.550000011920929,0.5199999809265137,0.5249999761581421,435124,0.0,0.0,0.5875999987125397,0.6971749991178513,0.7048249999682109,-10.65350964798456,-15.717000831062355,-1.0853759232014526,27.73132337794256,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-16,0.5299999713897705,0.5600000023841858,0.5289999842643738,0.5540000200271606,253235,0.0,0.0,0.5780000030994416,0.6912749990820884,0.7030916665991147,-4.152246184011153,-16.386386913031636,-1.680672390014804,35.01684638852615,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-17,0.5540000200271606,0.5730000138282776,0.5199999809265137,0.5299999713897705,536581,0.0,0.0,0.5662000000476837,0.684774997830391,0.701466666162014,-6.393505590756712,-17.315906415741633,-2.379538349690856,32.130025416856625,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-20,0.5509999990463257,0.5640000104904175,0.5299999713897705,0.550000011920929,204736,0.0,0.0,0.5572000026702881,0.678499998152256,0.6999666661024093,-1.292173495128216,-17.877670716625126,-3.066812891203105,36.805498391426234,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-21,0.550000011920929,0.5950000286102295,0.5400000214576721,0.593999981880188,498300,0.0,0.0,0.5593999981880188,0.6728999972343445,0.6990833327174186,6.185195531684625,-16.86729075833212,-3.745381166691027,45.67244708424926,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-22,0.593999981880188,0.6100000143051147,0.5609999895095825,0.5910000205039978,271206,0.0,0.0,0.5584999978542328,0.66737499833107,0.6983083327611287,5.819162537982224,-16.313916576003752,-4.4297530157985605,45.20670474487274,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-23,0.6039999723434448,0.6389999985694885,0.6000000238418579,0.621999979019165,556229,0.0,0.0,0.5616999983787536,0.6620249971747398,0.6977999990185102,10.735264520999912,-15.154261428818176,-5.126827442546525,50.79097388891874,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-24,0.6259999871253967,0.6259999871253967,0.5910000205039978,0.6079999804496765,197680,0.0,0.0,0.5660999953746796,0.656599996984005,0.6971916655699412,7.401516590238612,-13.783125498785218,-5.822167789793253,48.39232346754164,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-27,0.6079999804496765,0.6079999804496765,0.5640000104904175,0.5669999718666077,233395,0.0,0.0,0.5684999942779541,0.6501249969005585,0.6961833318074544,-0.263856187589158,-12.555278294443056,-6.615834192312208,42.11898204425014,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-28,0.5669999718666077,0.6000000238418579,0.5669999718666077,0.593999981880188,52978,0.0,0.0,0.5734999895095825,0.644549997150898,0.6953083316485087,3.574541019283312,-11.023195711019723,-7.300118837533214,46.99231360672103,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-29,0.5709999799728394,0.593999981880188,0.5709999799728394,0.5920000076293945,75024,0.0,0.0,0.5801999926567077,0.6397499978542328,0.694583331545194,2.033784061019217,-9.308324407543578,-7.894421187588405,46.67880125445285,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-30,0.6000000238418579,0.6259999871253967,0.5920000076293945,0.593999981880188,212698,0.0,0.0,0.5841999888420105,0.6353249967098236,0.693974998096625,1.6775065431964176,-8.047063807118505,-8.451313310661279,47.05916863823447,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-03-31,0.593999981880188,0.6200000047683716,0.593999981880188,0.6119999885559082,191403,0.0,0.0,0.5923999905586242,0.6313749969005584,0.6935416648785273,3.3085750016304787,-6.173036077333411,-8.963652960757198,50.48283976717028,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-03,0.6240000128746033,0.6240000128746033,0.5879999995231628,0.6159999966621399,90335,0.0,0.0,0.5989999890327453,0.6270249962806702,0.6930499980847041,2.838064764716589,-4.469519941654811,-9.526729959815162,51.237514836574626,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-04,0.6159999966621399,0.6159999966621399,0.5680000185966492,0.578000009059906,529847,0.0,0.0,0.5973999917507171,0.6216249957680702,0.6923333317041397,-3.247402570923759,-3.897044710600966,-10.213048064871426,44.32604354152053,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-05,0.5820000171661377,0.597000002861023,0.5640000104904175,0.5690000057220459,341172,0.0,0.0,0.595199990272522,0.6161749958992004,0.691449998319149,-4.401879196684804,-3.4040663393147015,-10.886543148880632,42.85171406398232,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-06,0.5950000286102295,0.640999972820282,0.5619999766349792,0.5759999752044678,368546,0.0,0.0,0.5905999898910522,0.6118249952793121,0.6905083313584328,-2.4720648385513364,-3.46913015192689,-11.394987215335615,44.40068469328415,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-11,0.6079999804496765,0.6079999804496765,0.5699999928474426,0.5699999928474426,110107,0.0,0.0,0.5867999911308288,0.6073249951004982,0.6894249980648358,-2.8629854358059417,-3.3795750438812373,-11.908474916747457,43.31691743261055,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-12,0.5699999928474426,0.6039999723434448,0.5419999957084656,0.5540000200271606,818745,0.0,0.0,0.5854999959468842,0.6040749952197075,0.6883249983191491,-5.380013003890981,-3.0749492066076103,-12.239858105571539,40.47942537962615,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-13,0.5529999732971191,0.578000009059906,0.5400000214576721,0.5479999780654907,239642,0.0,0.0,0.5808999955654144,0.6004999950528145,0.6871999979019165,-5.663628464637995,-3.2639466526017644,-12.616414888504798,39.436167814372496,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-14,0.550000011920929,0.574999988079071,0.5230000019073486,0.527999997138977,225800,0.0,0.0,0.5744999945163727,0.5969499945640564,0.6859416643778483,-8.093994398823344,-3.760784027492724,-12.973649864891602,36.09664778318067,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-17,0.527999997138977,0.5400000214576721,0.5019999742507935,0.5299999713897705,340890,0.0,0.0,0.568099993467331,0.5934249937534333,0.6849083309372266,-6.706569708797478,-4.267599200013604,-13.357019188043424,36.6741450257768,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-18,0.5299999713897705,0.5320000052452087,0.5099999904632568,0.5149999856948853,643838,0.0,0.0,0.5583999931812287,0.5902999937534332,0.6836166640122732,-7.7722077393109785,-5.404032002332883,-13.650438201893305,34.17931612162283,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-19,0.5199999809265137,0.5400000214576721,0.515999972820282,0.5230000019073486,109233,0.0,0.0,0.5490999937057495,0.5878749936819077,0.6823999971151352,-4.753231123216374,-6.595789988158416,-13.851846986054312,36.654356161812295,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-20,0.5230000019073486,0.5289999842643738,0.5130000114440918,0.5270000100135803,28451,0.0,0.0,0.543999993801117,0.5852749943733215,0.681291663646698,-3.1249970553771242,-7.05224056537721,-14.093328070306244,37.911502052279566,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-21,0.5270000100135803,0.5450000166893005,0.4959999918937683,0.5320000052452087,850724,0.0,0.0,0.5402999937534332,0.5828999951481819,0.6801666637261709,-1.536181492538043,-7.308286455538428,-14.300416907398986,39.527063153836785,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-24,0.5320000052452087,0.5550000071525574,0.5210000276565552,0.5400000214576721,434269,0.0,0.0,0.5366999983787537,0.5810249954462051,0.6791666636864344,0.6148729437091518,-7.628759074884807,-14.45030704356545,42.122028121919385,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-25,0.5550000071525574,0.5550000071525574,0.5299999713897705,0.5450000166893005,148786,0.0,0.0,0.5342000007629395,0.5784999951720238,0.678166663646698,2.0217176920510216,-7.657734620362641,-14.696485955050894,43.74675885464697,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-26,0.5559999942779541,0.6259999871253967,0.5509999990463257,0.6050000190734863,1250974,0.0,0.0,0.539300000667572,0.5766999959945679,0.6776249969998995,12.18246214066153,-6.485173502125042,-14.893931223341013,58.72147559110365,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-27,0.6050000190734863,0.6050000190734863,0.5799999833106995,0.5830000042915344,225297,0.0,0.0,0.5428000032901764,0.5743249967694283,0.6768166636427243,7.406042880929649,-5.489051261320611,-15.143194956470365,53.13604475779594,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-04-28,0.6140000224113464,0.7820000052452087,0.5830000042915344,0.652999997138977,2009841,0.0,0.0,0.5553000032901764,0.5743999972939491,0.6764666636784872,17.594092070938956,-3.3252078854029476,-15.088203434818276,64.6556865414432,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-02,0.7160000205039978,0.8349999785423279,0.699999988079071,0.7799999713897705,4510769,0.0,0.0,0.5803000032901764,0.5776499971747399,0.6772166634599368,34.41322884151959,0.45875636257207525,-14.702335553367135,76.12315038651745,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-03,0.7850000262260437,0.8399999737739563,0.6629999876022339,0.7049999833106995,2177248,0.0,0.0,0.5993000030517578,0.5790749967098237,0.677424996594588,17.63724006686064,3.492640237766811,-14.518212404202574,63.10240153841157,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-04,0.6970000267028809,0.6970000267028809,0.5839999914169312,0.6259999871253967,1687812,0.0,0.0,0.6096000015735626,0.5787249967455864,0.676799996693929,2.6902863368603582,5.3350045361094365,-14.490987060789728,52.8482371966078,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-05,0.6259999871253967,0.6389999985694885,0.5839999914169312,0.6010000109672546,636198,0.0,0.0,0.6170000016689301,0.5794499963521957,0.6760416636864345,-2.5931913546834537,6.480283985352046,-14.287827588543484,50.07508752221386,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-08,0.6010000109672546,0.6389999985694885,0.5809999704360962,0.5899999737739563,455807,0.0,0.0,0.6227999985218048,0.5791999951004982,0.6755249967177709,-5.266542200658039,7.527624963764272,-14.259280128092207,48.86019668108633,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-09,0.5899999737739563,0.6589999794960022,0.5899999737739563,0.6140000224113464,400188,0.0,0.0,0.6301999986171722,0.579799996316433,0.6752666637301445,-2.5706087339531734,8.692653090882885,-14.137624814226388,51.61823262364678,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-10,0.6140000224113464,0.6140000224113464,0.5699999928474426,0.5879999995231628,381889,0.0,0.0,0.6344999969005585,0.5803999960422516,0.6749749968449275,-7.328604823410788,9.321158033634545,-14.011630244787288,48.56267974718999,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-11,0.5879999995231628,0.5879999995231628,0.5360000133514404,0.5529999732971191,639097,0.0,0.0,0.6292999923229218,0.580649995803833,0.6745166634519895,-12.124586041095913,8.378540750997383,-13.916137692992317,44.72461247836893,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-12,0.5529999732971191,0.6000000238418579,0.5210000276565552,0.5410000085830688,664839,0.0,0.0,0.6250999927520752,0.5805749952793121,0.6737666636705398,-13.453845007859686,7.669120756973399,-13.831445427047251,43.45649094856707,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-15,0.5400000214576721,0.6010000109672546,0.5400000214576721,0.5979999899864197,747372,0.0,0.0,0.6195999920368195,0.5823999956250191,0.6736416637897491,-3.486120453196557,6.387362069238711,-13.544540527886282,50.61883313628821,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-16,0.5979999899864197,0.6399999856948853,0.5979999899864197,0.6299999952316284,302447,0.0,0.0,0.6045999944210052,0.5842999950051307,0.6738916635513306,4.2011248833946,3.4742426132822755,-13.294669364814837,54.131574393171206,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-17,0.6119999885559082,0.6359999775886536,0.5910000205039978,0.625,64785,0.0,0.0,0.5965999960899353,0.5866749957203865,0.6740999966859818,4.760309100937959,1.6917374086075971,-12.969144250911594,53.49129117575531,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-19,0.625,0.625,0.5820000171661377,0.609000027179718,487927,0.0,0.0,0.5949000000953675,0.5881499961018563,0.6740666637818019,2.3701507954429633,1.1476670982315627,-12.746019391897597,51.39627471344916,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-22,0.5799999833106995,0.6499999761581421,0.5299999713897705,0.5789999961853027,486336,0.0,0.0,0.5926999986171723,0.5877749964594841,0.6738083302974701,-2.311456464287665,0.8379060333213226,-12.768220570975194,47.62951706480138,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-23,0.5789999961853027,0.6029999852180481,0.550000011920929,0.5759999752044678,387840,0.0,0.0,0.5912999987602234,0.5873999953269958,0.6735416635870933,-2.5875230150237045,0.6639433885348499,-12.789360022857565,47.256537356240955,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-24,0.5730000138282776,0.5730000138282776,0.5199999809265137,0.5400000214576721,552395,0.0,0.0,0.583899998664856,0.5853499963879585,0.6729083304603894,-7.518406800405107,-0.2477146548304534,-13.011926009672884,42.91375668815248,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-25,0.5299999713897705,0.550000011920929,0.5199999809265137,0.5460000038146973,418515,0.0,0.0,0.5796999990940094,0.5837999969720841,0.672524997095267,-5.813350928407888,-0.7022949467865007,-13.19281818614908,43.84008545649436,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-26,0.5540000200271606,0.5540000200271606,0.5049999952316284,0.5389999747276306,779613,0.0,0.0,0.5782999992370605,0.5830999970436096,0.6720249970753988,-6.795784983793474,-0.8231860454271384,-13.232394690492754,42.96414533481884,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-29,0.5389999747276306,0.5590000152587891,0.5070000290870667,0.5320000052452087,536941,0.0,0.0,0.5773999989032745,0.5815499976277352,0.6713166639208794,-7.862832307637596,-0.7136099632687412,-13.371732167179454,42.05915374599168,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-30,0.5320000052452087,0.550000011920929,0.5,0.5199999809265137,927723,0.0,0.0,0.5695999979972839,0.5797499969601632,0.6699833303689957,-8.707868196131338,-1.7507544659076064,-13.467996787194124,40.4848045187089,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-05-31,0.5199999809265137,0.5289999842643738,0.5019999742507935,0.5040000081062317,269959,0.0,0.0,0.5569999992847443,0.5774999976158142,0.6680333306392033,-9.515258751628554,-3.549783275446457,-13.552217961454549,38.41981606079535,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-01,0.5040000081062317,0.5249999761581421,0.49000000953674316,0.4950000047683716,63781,0.0,0.0,0.5439999997615814,0.5745749980211258,0.6661583304405212,-9.00735202475828,-5.3213241726226626,-13.747982759418868,37.26829157923543,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-02,0.4950000047683716,0.5099999904632568,0.47999998927116394,0.49149999022483826,473888,0.0,0.0,0.5322499960660935,0.5714624978601932,0.6641958303749561,-7.656177762788556,-6.8617804214499785,-13.961745659019343,36.806281238195794,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-05,0.49149999022483826,0.527999997138977,0.49149999022483826,0.5099999904632568,262033,0.0,0.0,0.5253499954938888,0.5697624973952771,0.6622958304981391,-2.921862598704554,-7.794914917079339,-13.971601336107467,40.97170346790117,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-07,0.5099999904632568,0.5260000228881836,0.49000000953674316,0.49799999594688416,300715,0.0,0.0,0.5175499975681305,0.567987497150898,0.6602291638652483,-3.777413141359883,-8.880036943730076,-13.971159070636977,39.16821688681455,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-08,0.5,0.5590000152587891,0.5,0.5419999957084656,508181,0.0,0.0,0.5177499949932098,0.567137497663498,0.658454163869222,4.683727851233252,-8.70820618875591,-13.868340609941185,48.17596844498959,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-09,0.5519999861717224,0.5519999861717224,0.5099999904632568,0.5189999938011169,168458,0.0,0.0,0.5150499939918518,0.5658624976873398,0.6566124970714251,0.766915805328138,-8.97965564128333,-13.820936974066415,44.46912441979441,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-12,0.5189999938011169,0.550000011920929,0.5139999985694885,0.550000011920929,254179,0.0,0.0,0.5161499977111816,0.565762497484684,0.655179163813591,6.558173856408408,-8.7691389927883,-13.647666358685893,50.04798640140948,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-13,0.550000011920929,0.550000011920929,0.5220000147819519,0.5389999747276306,166269,0.0,0.0,0.5168499946594238,0.5655374974012375,0.6537541637818018,4.2855722737895015,-8.609067120313483,-13.493859200873512,48.1976370497964,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-14,0.5389999747276306,0.5730000138282776,0.5199999809265137,0.5550000071525574,260564,0.0,0.0,0.5203499972820282,0.566212497651577,0.6523874973257383,6.6589814646907595,-8.099874262713746,-13.209173999717835,51.03345271984006,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-15,0.5550000071525574,0.5799999833106995,0.550000011920929,0.5759999752044678,120340,0.0,0.0,0.5275499939918518,0.5673624977469445,0.6513958305120469,9.183960148687698,-7.017119374860395,-12.900502095484057,54.55021276534056,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-16,0.5799999833106995,0.5799999833106995,0.5490000247955322,0.5550000071525574,148455,0.0,0.0,0.5335499942302704,0.5683624982833863,0.6504624972740809,4.020244242197397,-6.1250529650107755,-12.621788240637144,50.63396738686146,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-19,0.5550000071525574,0.5550000071525574,0.5210000276565552,0.531000018119812,149760,0.0,0.0,0.5374999970197678,0.5685624986886978,0.6492624973257383,-1.2092984066968733,-5.463339868628495,-12.429487144173194,46.523224213004625,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-20,0.531000018119812,0.5590000152587891,0.531000018119812,0.5450000166893005,41436,0.0,0.0,0.5409999996423721,0.5690124988555908,0.6480124975244205,0.7393746856881032,-4.923002441872187,-12.191122697576144,49.118252161191556,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-21,0.5199999809265137,0.5440000295639038,0.5199999809265137,0.5429999828338623,167970,0.0,0.0,0.54549999833107,0.5692874982953071,0.6466208308935165,-0.4582979843916331,-4.178468706140075,-11.959610470845536,48.754267152765166,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-22,0.5419999957084656,0.5419999957084656,0.503000020980835,0.5080000162124634,242764,0.0,0.0,0.5421000003814698,0.568487498164177,0.6450208311279615,-6.290349408782625,-4.641702388868824,-11.86524981370742,42.779858776865126,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-26,0.5080000162124634,0.5389999747276306,0.5080000162124634,0.5180000066757202,119332,0.0,0.0,0.54200000166893,0.5678124979138375,0.6434208313624065,-4.428043343045917,-4.545954226041773,-11.750992470739984,44.85895183645744,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-27,0.5320000052452087,0.5320000052452087,0.503000020980835,0.503000020980835,45075,0.0,0.0,0.5373000025749206,0.5652624979615212,0.6414458314577739,-6.383767249154794,-4.946815946120671,-11.876814808058791,42.371932199196465,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-28,0.503000020980835,0.5379999876022339,0.5,0.515999972820282,440417,0.0,0.0,0.5350000023841858,0.5635874971747399,0.6395791644851366,-3.5514073792956333,-5.07241465324604,-11.881510769909195,45.20716947873456,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-29,0.5270000100135803,0.5270000100135803,0.5099999904632568,0.5120000243186951,62346,0.0,0.0,0.5307000041007995,0.5600624978542328,0.6370124980807305,-3.523644175166174,-5.242717351354494,-12.079825821054076,44.482004138956405,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-06-30,0.5090000033378601,0.5220000147819519,0.5090000033378601,0.5090000033378601,108242,0.0,0.0,0.5240000069141388,0.553287498652935,0.6340041647354762,-2.862596064571539,-5.293358662558104,-12.731251712868216,43.91304917345463,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-03,0.5260000228881836,0.5289999842643738,0.5139999985694885,0.5230000019073486,147785,0.0,0.0,0.5208000063896179,0.5487374991178513,0.6309624979893367,0.42242616949680095,-5.09123082952152,-13.031677656518184,47.30061303940717,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-04,0.5230000019073486,0.7889999747276306,0.5230000019073486,0.7120000123977661,10916166,0.0,0.0,0.5389000058174134,0.5508874997496604,0.6298958316445351,32.12098807046615,-2.1760330262884064,-12.54307901809722,71.94005891907665,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-05,0.7139999866485596,0.7149999737739563,0.6399999856948853,0.6650000214576721,2071158,0.0,0.0,0.5509000062942505,0.5524875000119209,0.628745832045873,20.711565412921367,-0.2873356804699048,-12.128642155100327,63.934670082425264,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-06,0.6600000262260437,0.6600000262260437,0.5989999771118164,0.6069999933242798,977796,0.0,0.0,0.5573000073432922,0.552912500500679,0.6266041651368142,8.917994854856119,0.7935264329600474,-11.760481135653668,55.697757358469836,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-07,0.6069999933242798,0.6190000176429749,0.5370000004768372,0.5540000200271606,1341281,0.0,0.0,0.561900007724762,0.5514125004410744,0.6235624983906746,-1.4059419094137207,1.9019349897397482,-11.570612109581479,49.43078635613939,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-10,0.5540000200271606,0.746999979019165,0.5440000295639038,0.6309999823570251,1902585,0.0,0.0,0.5732000052928925,0.5524875000119209,0.6213208317756653,10.083736310260175,3.748954552007903,-11.078548833945652,57.00055152345061,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-11,0.6119999885559082,0.6919999718666077,0.6119999885559082,0.6660000085830688,970779,0.0,0.0,0.5895000040531159,0.5553125008940697,0.6180541654427846,12.977099915856844,6.156444002971889,-10.151483163901286,59.936243050711596,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-12,0.6660000085830688,0.6890000104904175,0.640999972820282,0.6779999732971191,286258,0.0,0.0,0.6057000041007996,0.5587375000119209,0.6158708319067955,11.936597111907481,8.40511046562594,-9.276836787023063,60.92134996976899,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-13,0.6600000262260437,0.6779999732971191,0.6370000243186951,0.6610000133514404,172370,0.0,0.0,0.6206000030040741,0.5603125005960464,0.613295831779639,6.5098308333558075,10.759621165670117,-8.639114834654508,58.71862543153004,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-14,0.6610000133514404,0.6610000133514404,0.6029999852180481,0.628000020980835,165299,0.0,0.0,0.6325000047683715,0.5602625012397766,0.6119458317756653,-0.7114598819939172,12.893510340018151,-8.445736183204433,54.592218630561284,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-17,0.6200000047683716,0.6259999871253967,0.6000000238418579,0.6050000190734863,131265,0.0,0.0,0.6407000064849854,0.5597625017166138,0.6104041650891304,-5.572028570337725,14.459258081804688,-8.296415108032889,51.85693886547181,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-18,0.5849999785423279,0.625,0.5849999785423279,0.5950000286102295,113771,0.0,0.0,0.6290000081062317,0.5594125017523766,0.6086874986688297,-5.405402075966261,12.439390634973329,-8.095286501565276,50.66826306265289,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-19,0.5950000286102295,0.625,0.5870000123977661,0.5950000286102295,122684,0.0,0.0,0.6220000088214874,0.5598125025629997,0.6068291654189427,-4.340832769828283,11.108631188795085,-7.747924050994419,50.66826306265289,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-20,0.5950000286102295,0.6240000128746033,0.5809999704360962,0.5830000042915344,101874,0.0,0.0,0.6196000099182128,0.5599875032901764,0.6049208323160807,-5.90703761149223,10.645328025676704,-7.427968525049229,49.101849959160084,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-21,0.5830000042915344,0.6190000176429749,0.574999988079071,0.5899999737739563,215197,0.0,0.0,0.6232000052928924,0.5612375020980835,0.6028708318869272,-5.327347759461706,11.040335502024265,-6.905845761111949,50.07150546076563,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-24,0.5899999737739563,0.6200000047683716,0.5640000104904175,0.6129999756813049,668679,0.0,0.0,0.6214000046253204,0.5629125013947487,0.6011041651169459,-1.3517909368346988,10.390158876495924,-6.3535849422648605,53.224684306855366,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-25,0.6190000176429749,0.6200000047683716,0.5860000252723694,0.6190000176429749,83161,0.0,0.0,0.616700005531311,0.5649125024676322,0.5993791654706001,0.37295477396377075,9.167349428002083,-5.750393905651776,54.040120739310964,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-26,0.6200000047683716,0.6259999871253967,0.6010000109672546,0.625,146923,0.0,0.0,0.6114000082015991,0.567237502336502,0.5977791657050451,2.2244016382015657,7.785540568666168,-5.109188329191926,54.887065012071346,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-27,0.6259999871253967,0.6480000019073486,0.6259999871253967,0.6389999985694885,250755,0.0,0.0,0.6092000067234039,0.5702125027775764,0.5965708325306575,4.891659802560501,6.837363922382357,-4.418306815515744,56.88361856271029,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-28,0.6389999985694885,0.6800000071525574,0.6389999985694885,0.6679999828338623,268389,0.0,0.0,0.6132000029087067,0.5743125021457672,0.5957124988238017,8.936722058906161,6.771139513356676,-3.5923363569318236,60.757862726309966,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-07-31,0.6679999828338623,0.6790000200271606,0.6449999809265137,0.6620000004768372,120160,0.0,0.0,0.6189000010490417,0.5784875020384789,0.5948124989867211,6.963968226650586,6.985889732821709,-2.7445618537021756,59.565317017216884,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-01,0.6620000004768372,0.6759999990463257,0.6449999809265137,0.6629999876022339,114655,0.0,0.0,0.6256999969482422,0.5827750019729138,0.593754165371259,5.961321853271025,7.365620493331231,-1.849109284392182,59.70726473513459,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-02,0.6629999876022339,0.6639999747276306,0.6309999823570251,0.6589999794960022,66090,0.0,0.0,0.6320999920368194,0.5865000016987324,0.5926291649540265,4.255653820292384,7.7749343914768465,-1.03423247078459,58.81778878099333,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-03,0.6589999794960022,0.6589999794960022,0.5709999799728394,0.6480000019073486,75514,0.0,0.0,0.6385999917984009,0.590250001847744,0.5914708316326142,1.4719715361216659,8.19144257506141,-0.2064057464170022,56.33247361433641,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-04,0.6399999856948853,0.6470000147819519,0.6029999852180481,0.628000020980835,108823,0.0,0.0,0.6423999965190887,0.5924000024795533,0.5904541651407877,-2.2415902266938903,8.440242037517756,0.329549261169418,52.02788719523059,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-07,0.628000020980835,0.628000020980835,0.6019999980926514,0.628000020980835,86005,0.0,0.0,0.6439000010490418,0.5951250031590462,0.5894374986489613,-2.4693244358289435,8.195756795813969,0.9649037468978544,52.02788719523059,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-08,0.6480000019073486,0.6489999890327454,0.6209999918937683,0.6439999938011169,81299,0.0,0.0,0.646399998664856,0.5974750027060509,0.5891041651368141,-0.3712878819146448,8.18862642574445,1.420943538447533,55.20382898127706,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-09,0.6439999938011169,0.6499999761581421,0.6209999918937683,0.6299999952316284,78667,0.0,0.0,0.6468999981880188,0.5997500032186508,0.5885958318909009,-2.6124598861845207,7.8616081227728705,1.8950476240914584,51.96219058117021,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-10,0.6299999952316284,0.6539999842643738,0.6299999952316284,0.6520000100135803,64706,0.0,0.0,0.648199999332428,0.6021750032901764,0.5884458318352699,0.5862404636016505,7.643126298962809,2.3331240892789333,56.304417946806474,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-11,0.6520000100135803,0.6520000100135803,0.6320000290870667,0.6510000228881836,11620,0.0,0.0,0.6465000033378601,0.6040500044822693,0.588279165327549,0.696058704886321,7.027563701779062,2.6808427162194763,56.05638431837471,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-14,0.6200000047683716,0.6499999761581421,0.6039999723434448,0.625,254728,0.0,0.0,0.6428000032901764,0.6058000043034554,0.5881541654467582,-2.7691355319021387,6.107626068650059,3.0002063903251384,49.9011744479728,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-15,0.625,0.6290000081062317,0.6100000143051147,0.6100000143051147,105210,0.0,0.0,0.6375000059604645,0.6077750042080879,0.5880708321928978,-4.313724140899103,4.890790431749878,3.350646033865326,46.714269274726924,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-16,0.6100000143051147,0.6190000176429749,0.6019999980926514,0.6190000176429749,37642,0.0,0.0,0.6335000097751617,0.6096250042319298,0.5879708324869474,-2.2888700723671884,3.9163428956317548,3.6828649566495493,48.826026659854016,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-17,0.6190000176429749,0.6190000176429749,0.5320000052452087,0.5590000152587891,859806,0.0,0.0,0.6246000111103058,0.610025005042553,0.587404166162014,-10.50272089091136,2.38924731728598,3.8509837320935643,38.01084340844415,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-18,0.5590000152587891,0.5590000152587891,0.5210000276565552,0.5410000085830688,540426,0.0,0.0,0.6159000098705292,0.6108500048518181,0.5867874994874,-12.161065122113794,0.8267176849636203,4.100718809694871,35.4723363558475,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-21,0.5410000085830688,0.5809999704360962,0.5299999713897705,0.5740000009536743,347343,0.0,0.0,0.6105000078678131,0.6122500047087669,0.586187499264876,-5.978707034192514,-0.28583043323718965,4.446103930325239,42.989462841164496,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-22,0.5740000009536743,0.6060000061988831,0.5659999847412109,0.5979999899864197,270617,0.0,0.0,0.6059000074863434,0.6146250039339065,0.5855291659633318,-1.3038483912053445,-1.419564188199106,4.969152633533679,47.75621364964356,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-23,0.5979999899864197,0.609000027179718,0.5799999833106995,0.6019999980926514,71716,0.0,0.0,0.6031000077724457,0.6167750045657158,0.5848958328366279,-0.18239258259292404,-2.2171775269814904,5.450401582531408,48.528658206830976,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-24,0.5809999704360962,0.5989999771118164,0.5799999833106995,0.5799999833106995,83798,0.0,0.0,0.5959000051021576,0.6184750035405159,0.5843124995628993,-2.668236559040187,-3.6501068449210874,5.846615296296442,44.62098191343676,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-25,0.5799999833106995,0.5860000252723694,0.5669999718666077,0.578000009059906,67279,0.0,0.0,0.5886000037193299,0.6202000036835671,0.5837124998370806,-1.8008825335445275,-5.095130567003335,6.2509375517348795,44.271973980736604,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-28,0.578000009059906,0.5889999866485596,0.5680000185966492,0.5789999961853027,203072,0.0,0.0,0.5840000033378601,0.6216000035405159,0.5831374997893969,-0.8561656034211848,-6.04890604705492,6.595786373712883,44.50569580821723,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-29,0.5789999961853027,0.6290000081062317,0.5789999961853027,0.5899999737739563,256898,0.0,0.0,0.5819999992847442,0.6185500025749207,0.5827208330233892,1.374566065127791,-5.908981187943555,6.148599384311591,47.13232000783883,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-30,0.5899999737739563,0.6200000047683716,0.5860000252723694,0.6200000047683716,111426,0.0,0.0,0.582099997997284,0.6174250021576881,0.5831208328406016,6.510909964178434,-5.721343327036553,5.882857786091782,53.58476969617723,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-08-31,0.6209999918937683,0.6890000104904175,0.6200000047683716,0.6869999766349792,725287,0.0,0.0,0.5948999941349029,0.6194250017404557,0.583845832447211,15.48159075610803,-3.9593183253247095,6.093932219077987,64.11775694260021,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-01,0.6880000233650208,0.7400000095367432,0.6499999761581421,0.6970000267028809,488754,0.0,0.0,0.6104999959468842,0.6230000019073486,0.584737499554952,14.168719300617733,-2.0064214963394797,6.54353489925282,65.38052549397634,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-04,0.6970000267028809,0.7229999899864197,0.6700000166893005,0.7070000171661377,126881,0.0,0.0,0.6237999975681305,0.6249000027775764,0.5859291662772497,13.337611401468493,-0.17602899736862293,6.651117360811927,66.64465538493852,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-05,0.7070000171661377,0.7070000171661377,0.6620000004768372,0.6679999828338623,127997,0.0,0.0,0.6307999968528748,0.6249500021338463,0.5869708329439163,5.897271110745404,0.9360740377716763,6.470367360410031,57.782884208336974,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-06,0.6679999828338623,0.6990000009536743,0.6060000061988831,0.6600000262260437,428779,0.0,0.0,0.636599999666214,0.6245000034570694,0.5879374995827675,3.675781742396953,1.9375494222837735,6.218773917337908,56.13400604100233,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-07,0.6499999761581421,0.6790000200271606,0.6230000257492065,0.6230000257492065,348123,0.0,0.0,0.6409000039100647,0.6235500037670135,0.588754166662693,-2.7929439930803994,2.7824553024193324,5.91007912547915,49.148492552417814,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-08,0.6230000257492065,0.7200000286102295,0.6230000257492065,0.6919999718666077,572114,0.0,0.0,0.6523000001907349,0.6251500025391579,0.5899041662613551,6.086152332402942,4.342957296857147,5.974841049382791,59.3162463141081,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-11,0.6930000185966492,0.6930000185966492,0.6340000033378601,0.6449999809265137,436840,0.0,0.0,0.6588999986648559,0.6261500015854835,0.5908624996741613,-2.1095792633947767,5.230375628275283,5.972201981134695,51.72892696039631,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-12,0.6439999938011169,0.6669999957084656,0.621999979019165,0.6510000228881836,215033,0.0,0.0,0.6650000035762786,0.6275500014424324,0.5917041664322217,-2.105260242527079,5.967652306233263,6.058067028047001,52.563130299194,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-13,0.6510000228881836,0.6899999976158142,0.621999979019165,0.6790000200271606,267341,0.0,0.0,0.6709000051021576,0.6296500012278556,0.5924125000834465,1.207335648144707,6.551259238285077,6.285738592478034,56.35383090148402,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-14,0.6700000166893005,0.6700000166893005,0.6399999856948853,0.652999997138977,112354,0.0,0.0,0.6675000071525574,0.6314000010490417,0.5929291665554046,-2.172286121079604,5.717454235593481,6.488268188446804,52.183797190613745,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-15,0.6520000100135803,0.6800000071525574,0.640999972820282,0.6800000071525574,151890,0.0,0.0,0.665800005197525,0.6336500018835067,0.5934125001231829,2.1327728813729263,5.07377940794655,6.780696691082705,55.83836592590302,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-18,0.6800000071525574,0.6800000071525574,0.6470000147819519,0.6600000262260437,244929,0.0,0.0,0.6611000061035156,0.6348250031471252,0.593845833837986,-0.1663863057504897,4.1389363724070245,6.900641037471564,52.62957617392865,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-19,0.6600000262260437,0.6869999766349792,0.6420000195503235,0.6869999766349792,136641,0.0,0.0,0.6630000054836274,0.6365250021219253,0.5948458338777224,3.6199051210934807,4.159302976857901,7.006717685572725,56.28204461716027,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-20,0.6869999766349792,0.75,0.6869999766349792,0.7009999752044678,942414,0.0,0.0,0.6671000003814698,0.6384250015020371,0.5957375004887581,5.081693120013923,4.491521919092826,7.165488319647009,58.086646158466195,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-21,0.7020000219345093,0.722000002861023,0.6819999814033508,0.7210000157356262,230697,0.0,0.0,0.6768999993801117,0.6404750019311904,0.59681250055631,6.514997251573383,5.687184876707269,7.315949537615436,60.58942145490306,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-22,0.7210000157356262,0.7350000143051147,0.7009999752044678,0.734000027179718,135712,0.0,0.0,0.6811000049114228,0.6421250030398369,0.5979791676004728,7.766850959746349,6.069690743558835,7.382503911718081,62.17065426838431,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-25,0.734000027179718,1.0800000429153442,0.7300000190734863,0.9819999933242798,3580151,0.0,0.0,0.7148000061511993,0.6501250028610229,0.6010625009735425,37.381083502195786,9.948087368668999,8.162628979184984,79.26342796746414,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-26,0.9800000190734863,1.0800000429153442,0.7960000038146973,0.824999988079071,2923691,0.0,0.0,0.7322000026702881,0.6541750028729438,0.6028041675686836,12.674130711601636,11.927236512352417,8.521977462673568,60.59679145578353,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-27,0.824999988079071,0.8980000019073486,0.8059999942779541,0.843999981880188,841231,0.0,0.0,0.7486999988555908,0.6588000029325485,0.6050208340088526,12.728727550456249,13.646022392663342,8.888812731845352,61.77015930463044,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-28,0.8299999833106995,1.031999945640564,0.8289999961853027,0.8790000081062317,1595534,0.0,0.0,0.7712999999523162,0.6645750030875206,0.6076041673620541,13.963439408864742,16.059134991380436,9.376307600523608,63.90260533488961,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-09-29,0.8799999952316284,0.9190000295639038,0.8240000009536743,0.847000002861023,1004135,0.0,0.0,0.7879999995231628,0.6700500026345253,0.6098625009258588,7.4873100727871105,17.603163409428806,9.86902811982918,60.5757005716057,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-02,0.8460000157356262,0.8460000157356262,0.75,0.8149999976158142,1244586,0.0,0.0,0.8034999966621399,0.6747250020503998,0.611904167632262,1.431238456931805,19.08555251701212,10.266449836617461,57.35971934387549,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-03,0.8149999976158142,0.8230000138282776,0.7580000162124634,0.8090000152587891,617931,0.0,0.0,0.8157000005245209,0.6788500025868416,0.6140291675925255,-0.8213786026018741,20.159092202429918,10.556637765020918,56.75133816082895,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-04,0.8090000152587891,0.9869999885559082,0.7770000100135803,0.9010000228881836,3462499,0.0,0.0,0.8357000052928925,0.6856250032782555,0.6169708346327146,7.81381083902292,21.888787791732593,11.127619782288571,63.19708882758658,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-05,0.9629999995231628,1.2400000095367432,0.8130000233650208,0.8619999885559082,14264577,0.0,0.0,0.8498000025749206,0.6908750027418137,0.6197541678945223,1.4356302593576433,23.00343755417341,11.475652529923062,59.17110247631926,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-06,0.828000009059906,0.8560000061988831,0.7599999904632568,0.8230000138282776,1552730,0.0,0.0,0.8587000012397766,0.695175002515316,0.6221958349148432,-4.157445832066613,23.522853689040378,11.729292210781376,55.37225828952824,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-09,0.8230000138282776,0.8500000238418579,0.781000018119812,0.8270000219345093,569755,0.0,0.0,0.8432000041007995,0.7002250030636787,0.6247958352168401,-1.9212502475692173,20.418436989762647,12.072610538554624,55.686496603145365,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-10,0.8270000219345093,0.8700000047683716,0.800000011920929,0.8149999976158142,549820,0.0,0.0,0.8422000050544739,0.7053500026464462,0.6272291685144107,-3.229637529733852,19.401715729009954,12.454910908729635,54.44786817634766,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-11,0.8100000023841858,0.8100000023841858,0.7620000243186951,0.7990000247955322,625398,0.0,0.0,0.8377000093460083,0.7098500028252601,0.6294958353042602,-4.619790392588048,18.01084820904344,12.764844978229528,52.762712365888184,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-12,0.7940000295639038,0.7940000295639038,0.7630000114440918,0.7639999985694885,435887,0.0,0.0,0.826200008392334,0.7149750024080277,0.6314291685819626,-7.528444588602426,15.55648877369163,13.231228138175627,49.17715719159348,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-13,0.7639999985694885,0.7639999985694885,0.703000009059906,0.7049999833106995,362574,0.0,0.0,0.8120000064373016,0.7190750017762184,0.6328041682640712,-13.177342645115377,12.922852891776953,13.633101335095215,43.77658679671262,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-16,0.7049999833106995,0.7950000166893005,0.6600000262260437,0.7409999966621399,653497,0.0,0.0,0.8046000063419342,0.72325000166893,0.6344375014305115,-7.90454998489845,11.24784023301563,13.998620831550262,47.560734122045154,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-17,0.7409999966621399,0.8320000171661377,0.7059999704360962,0.75,377777,0.0,0.0,0.7987000048160553,0.7270500019192696,0.6356458346048991,-6.097408854688959,9.854893433414995,14.379731973101809,48.49405901021097,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-18,0.7490000128746033,0.8190000057220459,0.7200000286102295,0.765999972820282,240326,0.0,0.0,0.7851999998092651,0.7311500012874603,0.6371708343426387,-2.4452403201282578,7.392463711499661,14.749445812562783,50.19129696373974,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-19,0.765999972820282,0.8100000023841858,0.7509999871253967,0.7870000004768372,92951,0.0,0.0,0.777700001001358,0.7363250017166137,0.6382875010371208,1.1958338001163078,5.61912188073007,15.359458006023424,52.40798611945539,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-20,0.7870000004768372,0.7879999876022339,0.7519999742507935,0.753000020980835,162565,0.0,0.0,0.7707000017166138,0.740700002014637,0.6380625014503797,-2.296610963585687,4.050222711000333,16.085806693067227,48.63413928894279,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-23,0.8019999861717224,0.8019999861717224,0.7300000190734863,0.7820000052452087,246471,0.0,0.0,0.7662000000476837,0.7457750022411347,0.6387041682998339,2.062125449822723,2.7387613885112425,16.76376000900582,51.820898742620024,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-24,0.7820000052452087,0.7820000052452087,0.7409999966621399,0.75,268377,0.0,0.0,0.7597000002861023,0.7497750028967858,0.6397375017404556,-1.2768198344674586,1.3237300991591996,17.200414366355666,48.262752679158076,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-25,0.7789999842643738,0.8629999756813049,0.7789999842643738,0.7799999713897705,332251,0.0,0.0,0.7577999949455261,0.7537750020623207,0.6412291680773099,2.929529769374076,0.5339780268903861,17.551577437201317,51.61679789650663,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-26,0.7799999713897705,0.8199999928474426,0.7039999961853027,0.7839999794960022,170538,0.0,0.0,0.7597999930381775,0.7562000021338463,0.6428458347916604,3.185046943874973,0.47606332903632675,17.63318064881339,52.063030078471,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-27,0.7839999794960022,0.7900000214576721,0.7519999742507935,0.7889999747276306,95506,0.0,0.0,0.7681999921798706,0.758500000834465,0.6443041677276293,2.7076259775448985,1.278838673003836,17.723901043444805,52.65088685873907,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-30,0.7889999747276306,0.800000011920929,0.7540000081062317,0.7739999890327454,79174,0.0,0.0,0.7714999914169312,0.7601750001311303,0.6458541676402092,0.32404376456605427,1.4897873889364064,17.700719174519072,50.644391105923816,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-10-31,0.7739999890327454,0.800000011920929,0.7699999809265137,0.777999997138977,135719,0.0,0.0,0.7742999911308288,0.7629250004887581,0.6477291678388913,0.477851743578681,1.490971017437292,17.78456774367759,51.178705111137226,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-01,0.7770000100135803,0.7770000100135803,0.7110000252723694,0.7599999904632568,92735,0.0,0.0,0.7736999928951264,0.7654249995946885,0.6495541676878929,-1.770712492914103,1.0810978612953221,17.838517196993937,48.62753857891512,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-02,0.7599999904632568,0.7599999904632568,0.6899999976158142,0.7319999933242798,428958,0.0,0.0,0.7681999921798706,0.7681499987840652,0.650670834382375,-4.712314400429558,0.006508285606261199,18.055083798738707,44.879790895288586,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-03,0.7310000061988831,0.7310000061988831,0.6899999976158142,0.7110000252723694,142070,0.0,0.0,0.7639999926090241,0.7686250001192093,0.6513458346327146,-6.937168566672663,-0.6017248345380296,18.00566753491668,42.24977833535884,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-06,0.7110000252723694,0.800000011920929,0.6840000152587891,0.7850000262260437,188012,0.0,0.0,0.7642999947071075,0.7721250012516976,0.6526791681845983,2.708364734042524,-1.0134377894647741,18.300849619474338,52.75609645416883,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-07,0.7850000262260437,0.7850000262260437,0.7319999933242798,0.7699999809265137,67123,0.0,0.0,0.7662999927997589,0.7751000002026558,0.6540208344658216,0.4828380740598024,-1.1353383306148952,18.51304413501244,50.740974995781,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-08,0.7699999809265137,1.1440000534057617,0.7509999871253967,1.0499999523162842,4755779,0.0,0.0,0.7932999908924103,0.7843749985098839,0.6579458341002464,32.35849796684143,1.1378476365873045,19.215740545349266,72.13626018931666,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-09,1.0499999523162842,1.090000033378601,0.8349999785423279,0.9190000295639038,2847285,0.0,0.0,0.8067999958992005,0.7910249993205071,0.660804167886575,13.906796509047245,1.9942475386042393,19.706417992249108,59.184275069358954,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-10,0.9190000295639038,0.9190000295639038,0.7699999809265137,0.8339999914169312,1149508,0.0,0.0,0.8112999975681305,0.7948749989271164,0.6632541676362356,2.7979778031361744,2.0663624674551047,19.844704747195625,52.586604760184045,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-13,0.8339999914169312,0.8960000276565552,0.7799999713897705,0.8510000109672546,716445,0.0,0.0,0.8189999997615814,0.7996499985456467,0.6657958343625069,3.907205276555396,2.4198088227508716,20.10438595058256,53.69832612658346,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-14,0.8510000109672546,0.8790000081062317,0.8299999833106995,0.8700000047683716,221473,0.0,0.0,0.8282000005245209,0.8042249992489815,0.6685541679461797,5.047090584083267,2.981131063810285,20.29316961998562,54.96917390082118,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-15,0.8700000047683716,0.8700000047683716,0.8240000009536743,0.8489999771118164,272108,0.0,0.0,0.8370999991893768,0.8079249992966652,0.6711958343784015,1.421571847325668,3.6111025055679433,20.370979364746717,53.230149725289984,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-16,0.8460000157356262,0.8460000157356262,0.8019999861717224,0.8199999928474426,151937,0.0,0.0,0.8458999991416931,0.8103999987244606,0.6736958344777425,-3.0618283863967815,4.3805528718050635,20.29167426167817,50.83826782258668,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-17,0.8199999928474426,0.8460000157356262,0.8100000023841858,0.8389999866485596,163133,0.0,0.0,0.8586999952793122,0.8130249977111816,0.6764875009655953,-2.294166616868878,5.617908145101842,20.18329925544779,52.34902348477431,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-20,0.8199999928474426,0.824999988079071,0.7950000166893005,0.8009999990463257,138199,0.0,0.0,0.8602999925613404,0.8084999978542328,0.6790375009179115,-6.892943627543567,6.406925769274623,19.065588684176653,49.0992254323866,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-21,0.8009999990463257,0.8009999990463257,0.7400000095367432,0.7860000133514404,372372,0.0,0.0,0.861899995803833,0.807524998486042,0.6814916677772999,-8.806124007647322,6.733537341845018,18.493744922781318,47.83681062680931,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-22,0.7860000133514404,0.8080000281333923,0.7670000195503235,0.7919999957084656,352362,0.0,0.0,0.8361000001430512,0.8062249988317489,0.68384166782101,-5.274489227011171,3.7055414251099013,17.896442520196327,48.40822572846436,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-23,0.7919999957084656,0.7919999957084656,0.7639999985694885,0.7789999842643738,179303,0.0,0.0,0.8220999956130981,0.8037249982357025,0.6861833343903224,-5.242672616313737,2.286229421472699,17.129775375529416,47.201735013918366,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-24,0.7789999842643738,0.7789999842643738,0.7419999837875366,0.7609999775886536,274364,0.0,0.0,0.8147999942302704,0.8015749976038933,0.688008334239324,-6.602849413670027,1.6498763890977022,16.50658250966261,45.51040207791901,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-27,0.7609999775886536,0.8209999799728394,0.7350000143051147,0.7889999747276306,290627,0.0,0.0,0.8085999906063079,0.8009249970316887,0.6902583340803782,-2.4239446087528096,0.9582662050833135,16.03264422714291,48.595991483501464,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-28,0.7900000214576721,0.7940000295639038,0.7699999809265137,0.7929999828338623,134614,0.0,0.0,0.800899988412857,0.8005249962210655,0.692283333837986,-0.9863910217616765,0.04684328329054895,15.635456913716652,49.03994954722189,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-29,0.7929999828338623,0.8270000219345093,0.7710000276565552,0.7900000214576721,212322,0.0,0.0,0.7949999928474426,0.7977499961853027,0.6943750008940697,-0.6289272244974674,-0.34471994371797576,14.887488051575668,48.70023395188937,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-11-30,0.7900000214576721,0.8259999752044678,0.7710000276565552,0.800000011920929,262492,0.0,0.0,0.7929999947547912,0.7961999967694282,0.6964166676004727,0.8827260040906131,-0.40190932273561447,14.328107555604944,49.944982681324106,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-01,0.7730000019073486,0.8240000009536743,0.75,0.7730000019073486,482456,0.0,0.0,0.7863999962806701,0.7949499964714051,0.6980583344896635,-1.7039667391528044,-1.0755393708643761,13.880166913640126,46.65344346192228,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-04,0.7699999809265137,0.7699999809265137,0.7319999933242798,0.7540000081062317,371946,0.0,0.0,0.7816999971866607,0.7931249961256981,0.6997166678309441,-3.5435575259206002,-1.4405042073880976,13.34945022594803,44.434230169403804,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-05,0.7400000095367432,0.753000020980835,0.6909999847412109,0.7099999785423279,661607,0.0,0.0,0.7740999937057496,0.790499995648861,0.7012083341677984,-8.280585930063621,-2.074636563362649,12.733970366600806,39.72195979687702,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-06,0.7089999914169312,0.7099999785423279,0.6669999957084656,0.6899999976158142,1001989,0.0,0.0,0.7638999938964843,0.787774994969368,0.702416667342186,-9.674040695264656,-3.030687851905227,12.152093137277339,37.76164961744267,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-07,0.6890000104904175,0.7440000176429749,0.6669999957084656,0.6880000233650208,568191,0.0,0.0,0.754799997806549,0.7858749955892563,0.703625001013279,-8.850023136678487,-3.954190928215875,11.689464481439757,37.56202109790173,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-08,0.5770000219345093,0.6380000114440918,0.44999998807907104,0.5879999995231628,2828786,0.0,0.0,0.7375,0.7829499959945678,0.7042916675408681,-20.27118650533386,-5.804967906901058,11.16843093264842,29.238798154228547,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-11,0.6000000238418579,0.6899999976158142,0.5600000023841858,0.5699999928474426,573296,0.0,0.0,0.7156000018119812,0.7786749958992004,0.7047250007589658,-20.34656352653196,-8.100297867453836,10.493454192854356,28.03461002773311,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-12,0.5699999928474426,0.6039999723434448,0.5600000023841858,0.578000009059906,249176,0.0,0.0,0.6941000044345855,0.774374996125698,0.7053500006596247,-16.726695668191887,-10.366423514800847,9.785921230810658,29.42579130790466,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-13,0.574999988079071,0.5809999704360962,0.5299999713897705,0.5770000219345093,337739,0.0,0.0,0.6728000044822693,0.7696499973535538,0.7058583344022433,-14.238998500227371,-12.583641032196944,9.03745976242279,29.349416919680138,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-14,0.5770000219345093,0.5770000219345093,0.5260000228881836,0.5609999895095825,158368,0.0,0.0,0.6489000022411346,0.7639999970793724,0.7062666674455007,-13.546002839877941,-15.065444408147025,8.174437828517043,28.093013639679953,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-15,0.5609999895095825,0.5699999928474426,0.5509999990463257,0.5550000071525574,94133,0.0,0.0,0.6271000027656555,0.7590499967336655,0.7066500008106231,-11.497368090435419,-17.38357084985384,7.415268642599937,27.615596716322287,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-18,0.5600000023841858,0.5789999961853027,0.550000011920929,0.5640000104904175,170969,0.0,0.0,0.6081000030040741,0.7535999968647957,0.7069916675488154,-7.25209542769253,-19.30732410642857,6.5924863694043765,29.54961350698666,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-19,0.5640000104904175,0.5789999961853027,0.5400000214576721,0.5730000138282776,219782,0.0,0.0,0.5944000065326691,0.7491749972105026,0.705833334227403,-3.600267912045413,-20.659390830463735,6.140495338115603,31.520054046094742,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-20,0.5730000138282776,0.5899999737739563,0.546999990940094,0.5659999847412109,147942,0.0,0.0,0.5820000052452088,0.7438249975442887,0.7050083339214325,-2.7491443917181244,-21.755788368680705,5.5058446482395755,30.798528392208127,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-21,0.5600000023841858,0.5600000023841858,0.503000020980835,0.5569999814033508,293569,0.0,0.0,0.5689000010490417,0.7381499975919723,0.7045916671554248,-2.091759469809711,-22.928943588033043,4.7628054660409385,29.8523545787192,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-22,0.5569999814033508,0.5669999718666077,0.5379999876022339,0.5590000152587891,121998,0.0,0.0,0.5660000026226044,0.7323999986052513,0.704633333782355,-1.236746878335755,-22.719824726861187,3.940583490969607,30.364333470042382,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-27,0.5649999976158142,0.6489999890327454,0.5429999828338623,0.6110000014305115,886244,0.0,0.0,0.5701000034809113,0.7283249989151954,0.704466667274634,7.174179564966387,-21.72450426251365,3.3867225731008643,42.180211979484916,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-28,0.6110000014305115,0.6140000224113464,0.5220000147819519,0.6000000238418579,871166,0.0,0.0,0.5723000049591065,0.7238749995827675,0.7039166674017906,4.840122076310434,-20.93938797596642,2.8353259846289154,40.610409870054845,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2023-12-29,0.8050000071525574,1.184000015258789,0.699999988079071,0.7300000190734863,14539463,0.0,0.0,0.5876000046730041,0.7231250002980232,0.7043500011165936,24.234175164741018,-18.741572420973533,2.665578072217772,59.6994276902593,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-02,0.7400000095367432,0.7639999985694885,0.6729999780654907,0.7139999866485596,907310,0.0,0.0,0.6029000043869018,0.7226750001311302,0.7047916675607363,18.427596857398765,-16.573839654408278,2.5373927351166867,57.260006144169374,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-03,0.7139999866485596,0.7200000286102295,0.671999990940094,0.699999988079071,217224,0.0,0.0,0.6174000024795532,0.7223999992012977,0.705391667286555,13.378682421086218,-14.534883283199749,2.411189797601242,55.13699820688788,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-04,0.699999988079071,0.7429999709129333,0.699999988079071,0.7429999709129333,276901,0.0,0.0,0.6352999985218049,0.72134999781847,0.706541666885217,16.952616502710725,-11.929021911263646,2.095889262771346,60.037874911448846,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-05,0.7429999709129333,0.7429999709129333,0.6949999928474426,0.7229999899864197,126963,0.0,0.0,0.650299996137619,0.7201749980449677,0.7076083332300186,11.17945475635765,-9.702503155071435,1.77593510771503,56.92314551853257,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-08,0.7200000286102295,0.7200000286102295,0.6600000262260437,0.6679999828338623,460847,0.0,0.0,0.6604999959468841,0.7106249988079071,0.7082166661818822,1.1355014281606906,-7.05365037046389,0.3400559095860659,49.342079084312836,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-09,0.6899999976158142,0.7120000123977661,0.6679999828338623,0.675000011920929,202356,0.0,0.0,0.672299998998642,0.7045249983668327,0.7089833329121272,0.40160834840227283,-4.574003682323808,-0.6288348876950418,50.250222290419245,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-10,0.675000011920929,0.699999988079071,0.621999979019165,0.6460000276565552,469504,0.0,0.0,0.6810000002384186,0.6998249992728234,0.7094500000278156,-5.139496706256955,-2.689958068655102,-1.3566848621629157,46.528780362417564,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-11,0.6460000276565552,0.7799999713897705,0.6460000276565552,0.7070000171661377,1393876,0.0,0.0,0.6906000018119812,0.6962249994277954,0.7102333337068558,2.374748814237832,-0.8079281296186067,-1.9723566346777948,54.21046045580017,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-12,0.7070000171661377,0.7099999785423279,0.671999990940094,0.7099999785423279,282990,0.0,0.0,0.7015999972820282,0.6922249987721443,0.7109916667143504,1.1972607315907835,1.354328220811597,-2.639506033724851,54.556225518879515,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-15,0.6990000009536743,0.7179999947547913,0.6800000071525574,0.7080000042915344,104240,0.0,0.0,0.699399995803833,0.6886999994516373,0.7116833334167798,1.2296266141404857,1.5536512793255999,-3.2294326543801324,54.26205139722604,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-16,0.7080000042915344,0.7080000042915344,0.656000018119812,0.6990000009536743,354376,0.0,0.0,0.6978999972343445,0.685674999654293,0.7121833334366481,0.15761623781185788,1.78291429412114,-3.7221221752605227,52.88021598108328,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-17,0.6980000138282776,0.6990000009536743,0.6620000004768372,0.6919999718666077,83384,0.0,0.0,0.6970999956130981,0.6819999992847443,0.7123833333452543,-0.7316057636759806,2.214075710291803,-4.265025954191545,51.77580970027357,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-18,0.6600000262260437,0.7059999704360962,0.6600000262260437,0.6629999876022339,126633,0.0,0.0,0.6890999972820282,0.678549998998642,0.7123916665712993,-3.7875503965663713,1.5547856899204449,-4.750430017736634,47.362607253623054,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-19,0.6940000057220459,0.7059999704360962,0.6600000262260437,0.6959999799728394,231424,0.0,0.0,0.6863999962806702,0.676299998164177,0.7126666665077209,1.398599030330376,1.4934198053984544,-5.102900142888887,52.34082856102104,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-22,0.6980000138282776,0.6980000138282776,0.6600000262260437,0.6800000071525574,157234,0.0,0.0,0.6875999987125396,0.6734999984502792,0.7128416667381923,-1.1052925500599853,2.093541246429767,-5.518991120136391,49.87775806024567,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-23,0.6980000138282776,0.6980000138282776,0.6600000262260437,0.6899999976158142,195344,0.0,0.0,0.6890999972820282,0.6712749987840653,0.7131916667024295,0.13060518608849556,2.655394365982763,-5.8773356273459445,51.416583392215045,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-24,0.6899999976158142,0.7099999785423279,0.6899999976158142,0.7080000042915344,167946,0.0,0.0,0.6952999949455261,0.6699499994516372,0.7138583332300186,1.8265510482282314,3.7838637979906156,-6.15084698664339,54.14554922491687,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-25,0.7080000042915344,0.7149999737739563,0.6890000104904175,0.6890000104904175,254645,0.0,0.0,0.6934999942779541,0.6674500003457069,0.7143666664759318,-0.6488801477528185,3.9029131648444864,-6.56758893323946,50.89574641745389,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-26,0.6890000104904175,0.718999981880188,0.671999990940094,0.671999990940094,180624,0.0,0.0,0.6896999955177308,0.6644250005483627,0.7145999997854233,-2.566333868735212,3.804040327878705,-7.021410474688904,48.113219890239215,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-29,0.6800000071525574,0.699999988079071,0.6620000004768372,0.6729999780654907,104498,0.0,0.0,0.6861999928951263,0.6614999994635582,0.7149583329757054,-1.9236396045333406,3.7339370297201127,-7.477125735376773,48.29229809542168,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-30,0.671999990940094,0.671999990940094,0.6010000109672546,0.6579999923706055,222797,0.0,0.0,0.6820999920368195,0.6579499989748001,0.7150083328286807,-3.53320626705316,3.6704906299337696,-7.980093550539366,45.74204819721023,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-01-31,0.6499999761581421,0.6499999761581421,0.6209999918937683,0.6380000114440918,197401,0.0,0.0,0.6766999959945679,0.6545749992132187,0.71489999939998,-5.718927852747724,3.3800552737184892,-8.43824314413098,42.51800284189828,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-01,0.6370000243186951,0.6380000114440918,0.6060000061988831,0.6370000243186951,135024,0.0,0.0,0.674099999666214,0.6516499996185303,0.7149999996026357,-5.503630821226719,3.44510090705528,-8.8601398628409,42.35724847231171,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-02,0.6259999871253967,0.6299999952316284,0.6060000061988831,0.6209999918937683,25116,0.0,0.0,0.6666000008583068,0.6494249999523163,0.7150916660825412,-6.84068540441411,2.64464732759774,-9.182971812545937,39.76653816407328,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-05,0.6209999918937683,0.6290000081062317,0.6000000238418579,0.6290000081062317,102973,0.0,0.0,0.6615000009536743,0.6479000002145767,0.7151749993364016,-4.913075253301272,2.0990894790235313,-9.406788434194175,41.687023563226084,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-06,0.6370000243186951,0.6370000243186951,0.6069999933242798,0.6290000081062317,31063,0.0,0.0,0.6554000020027161,0.646424999833107,0.7157583326101303,-4.028073514771669,1.3884057967941008,-9.686695860624909,41.687023563226084,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-07,0.6290000081062317,0.6359999775886536,0.6119999885559082,0.6349999904632568,87889,0.0,0.0,0.6481000006198883,0.6475999996066093,0.7165416657924653,-2.0212945755441534,0.07720830969467132,-9.621445545613785,43.26059490061601,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-08,0.6349999904632568,0.6349999904632568,0.6100000143051147,0.6110000014305115,29236,0.0,0.0,0.6402999997138977,0.648624999821186,0.7168499991297722,-4.575979743320043,-1.283484310592926,-9.517332690438534,38.755533636099734,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-09,0.6069999933242798,0.628000020980835,0.6000000238418579,0.6169999837875366,105095,0.0,0.0,0.6347999989986419,0.6495999991893768,0.7170083324114481,-2.80403516685314,-2.2783251553576878,-9.401331919723031,40.4258161284729,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-12,0.6169999837875366,0.6570000052452087,0.5929999947547913,0.6389999985694885,317905,0.0,0.0,0.6314000010490417,0.6511499986052514,0.7173166657487552,1.2036739796990465,-3.0330949241363285,-9.224192090175015,46.21770339524413,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-13,0.6380000114440918,0.6389999985694885,0.6129999756813049,0.6389999985694885,89813,0.0,0.0,0.62950000166893,0.653099998831749,0.7178083325425784,1.5091337371520388,-3.6135350183791255,-9.014709188680404,46.21770339524413,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-14,0.6209999918937683,0.7099999785423279,0.6000000238418579,0.6159999966621399,536580,0.0,0.0,0.6273000001907348,0.6546249985694885,0.7181249991059303,-1.8013715168434727,-4.174145264611848,-8.84247180024364,41.34410378429935,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-15,0.6159999966621399,0.6370000243186951,0.6110000014305115,0.625,132917,0.0,0.0,0.6260999977588654,0.6561499983072281,0.7185083324710528,-0.17569042689711512,-4.579745580414136,-8.678860264482323,43.83967836881622,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-16,0.625,0.6430000066757202,0.6119999885559082,0.6420000195503235,71745,0.0,0.0,0.6282000005245209,0.6578749984502792,0.7189416661858559,2.1967556533397317,-4.510735017391167,-8.493966980596467,48.31301434840349,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-19,0.6299999952316284,0.640999972820282,0.5600000023841858,0.6290000081062317,415389,0.0,0.0,0.6282000005245209,0.6594499990344047,0.7190166662136713,0.1273491851389469,-4.738797263726053,-8.284462652714799,45.33893697946469,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-20,0.6290000081062317,0.6290000081062317,0.6019999980926514,0.6169999837875366,114124,0.0,0.0,0.6269999980926514,0.6609499990940094,0.7184333329399427,-1.5948986181076628,-5.136546039472677,-8.001206404316237,42.72444319434205,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-21,0.6169999837875366,0.6330000162124634,0.6010000109672546,0.6299999952316284,209004,0.0,0.0,0.6264999985694886,0.6627249985933303,0.717874999344349,0.5586586863737469,-5.466068143005212,-7.682396071932902,46.33484050233907,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-22,0.6320000290870667,0.6320000290870667,0.6029999852180481,0.6150000095367432,99908,0.0,0.0,0.6268999993801116,0.6628249987959862,0.717108332614104,-1.8982277644178303,-5.4199825717394345,-7.569753599185851,42.96914959794341,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-23,0.6200000047683716,0.6200000047683716,0.5899999737739563,0.6000000238418579,324622,0.0,0.0,0.6252000033855438,0.6628249987959862,0.7165416662891706,-4.030706878954665,-5.676459922119377,-7.4966565128546545,39.851708975938934,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-26,0.6000000238418579,0.6000000238418579,0.5609999895095825,0.578000009059906,930977,0.0,0.0,0.6191000044345856,0.6590249985456467,0.7158583328127861,-6.638668241040565,-6.058191145884996,-7.9391873590165645,35.75449292104544,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-27,0.578000009059906,0.6110000014305115,0.578000009059906,0.6000000238418579,81824,0.0,0.0,0.6152000069618225,0.6561749994754791,0.7156666661302249,-2.470738450578055,-6.244522047687031,-8.312761998044566,42.158690414917444,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-28,0.6100000143051147,0.6119999885559082,0.5649999976158142,0.574999988079071,324345,0.0,0.0,0.6111000061035157,0.6530499994754791,0.7146916662653288,-5.907383024690979,-6.4237031476391,-8.624931519344901,37.57492467417505,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-02-29,0.5600000023841858,0.5860000252723694,0.550000011920929,0.5860000252723694,167251,0.0,0.0,0.6072000086307525,0.649125000834465,0.7141999999682108,-3.4914333097902115,-6.458693186954277,-9.111593270322363,40.633471698823925,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-01,0.5860000252723694,0.6179999709129333,0.5659999847412109,0.597000002861023,85914,0.0,0.0,0.6027000069618225,0.6459750011563301,0.7137499998013178,-0.9457448207994759,-6.699174753983214,-9.495621529086348,43.6088967062158,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-04,0.597000002861023,0.597000002861023,0.5720000267028809,0.5950000286102295,54026,0.0,0.0,0.5993000090122222,0.6441500023007393,0.7130499998728435,-0.7175004734406836,-6.962662909000124,-9.662716160772872,43.18509903739645,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-05,0.593999981880188,0.593999981880188,0.5659999847412109,0.578000009059906,41384,0.0,0.0,0.5954000115394592,0.6417250022292137,0.7124249999721844,-2.922405465623684,-7.218822786837274,-9.92385131708336,39.65720698355784,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-06,0.5770000219345093,0.593999981880188,0.5699999928474426,0.5709999799728394,21178,0.0,0.0,0.5895000100135803,0.6398500010371209,0.7115166664123536,-3.1382577992347755,-7.869030388673782,-10.072380417537383,38.27082070607977,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-07,0.5830000042915344,0.6100000143051147,0.5609999895095825,0.6000000238418579,150062,0.0,0.0,0.5880000114440918,0.6371750012040138,0.7110166663924853,2.0408183952743246,-7.717658361831585,-10.385363477219876,46.59974561331882,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-08,0.6000000238418579,0.6179999709129333,0.5910000205039978,0.6140000224113464,214348,0.0,0.0,0.5894000113010407,0.6347750023007392,0.7104083334406217,4.173737807707827,-7.148200675079688,-10.646458885635264,50.10010092497458,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-11,0.6140000224113464,0.6140000224113464,0.5860000252723694,0.6110000014305115,90436,0.0,0.0,0.5927000105381012,0.6323500022292137,0.7096583336591721,3.087563787251511,-6.270260386073375,-10.89373967206694,49.35353518642373,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-12,0.6110000014305115,0.6159999966621399,0.5899999737739563,0.6110000014305115,126916,0.0,0.0,0.5938000082969666,0.6301500022411346,0.7087416668732961,2.896596984374409,-5.76846684359104,-11.088901401674125,49.35353518642373,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-13,0.6100000143051147,0.6159999966621399,0.5910000205039978,0.6119999885559082,62041,0.0,0.0,0.5975000083446502,0.6281500026583672,0.7077249998847643,2.4267748968622764,-4.87940685887199,-11.243773674711788,49.64361896847991,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-14,0.6110000014305115,0.6179999709129333,0.5910000205039978,0.6179999709129333,139567,0.0,0.0,0.6007000029087066,0.6270250022411347,0.7046916663646698,2.8799680240480954,-4.198397071621756,-11.021368327540795,51.4407770859689,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-15,0.6179999709129333,0.6179999709129333,0.5920000076293945,0.6079999804496765,40120,0.0,0.0,0.601800000667572,0.6248250022530556,0.7028833329677582,1.0302392448034108,-3.6850320493670665,-11.105446245982217,48.34400864427607,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-18,0.6079999804496765,0.6110000014305115,0.5899999737739563,0.6110000014305115,183588,0.0,0.0,0.6033999979496002,0.6231000021100044,0.7009416664640109,1.25952991493813,-3.161611955335265,-11.105298497475356,49.32952887481119,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-19,0.6110000014305115,1.100000023841858,0.6110000014305115,0.8999999761581421,8178479,0.0,0.0,0.6355999946594239,0.6283500015735626,0.7011166661977768,41.59848705480131,1.1538144454054715,-10.378681342555277,82.9922677812595,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-20,0.8730000257492065,0.8730000257492065,0.7200000286102295,0.7319999933242798,2060503,0.0,0.0,0.6516999959945678,0.6289500012993813,0.7001583327849706,12.321620043462646,3.6171388263273943,-10.170318362469382,58.614430573692985,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-21,0.7319999933242798,0.753000020980835,0.6610000133514404,0.753000020980835,672981,0.0,0.0,0.6669999957084656,0.6305500015616416,0.6996416663130124,12.89355709530747,5.780666728499029,-9.875293036143997,60.1886307895641,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-22,0.75,0.75,0.652999997138977,0.6959999799728394,471630,0.0,0.0,0.6751999914646148,0.6311500012874603,0.6986999993522962,3.080567057340458,6.97932188660358,-9.667954505146065,54.166105546258876,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-25,0.6959999799728394,0.7689999938011169,0.6330000162124634,0.7590000033378601,853379,0.0,0.0,0.6899999916553498,0.6333000019192696,0.6975166658560435,10.000001814054425,8.953101147046581,-9.206470193506066,59.043995246043266,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-26,0.7590000033378601,0.9599999785423279,0.7319999933242798,0.7580000162124634,1869603,0.0,0.0,0.7046999931335449,0.635800002515316,0.6966499994198482,7.5635055482138736,10.83673959510077,-8.734658286830758,58.93677668435847,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-27,0.7559999823570251,0.8389999866485596,0.734000027179718,0.7580000162124634,539707,0.0,0.0,0.7192999958992005,0.6388000026345253,0.6961083327730496,5.380233634630267,12.601752181070571,-8.232674059543028,58.93677668435847,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-03-28,0.7599999904632568,0.7760000228881836,0.7269999980926514,0.7720000147819519,144260,0.0,0.0,0.7347000002861023,0.6421750023961067,0.6956499993801117,5.076904107979378,14.408065954726196,-7.687054845346969,60.11283895211387,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-02,0.7720000147819519,0.8330000042915344,0.7720000147819519,0.7960000038146973,509191,0.0,0.0,0.7535000026226044,0.64655000269413,0.6954916660984357,5.640345194979285,16.541644031060404,-7.036987758438333,62.11593418465953,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-03,0.7950000166893005,0.7950000166893005,0.7289999723434448,0.7549999952316284,300586,0.0,0.0,0.767900002002716,0.6497000023722649,0.6951249991854032,-1.6799071151769545,18.193012036149714,-6.53479544921712,56.86240352235769,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-04,0.7549999952316284,0.7549999952316284,0.7120000123977661,0.7400000095367432,129005,0.0,0.0,0.7519000053405762,0.6524750024080277,0.694924999276797,-1.5826566989373674,15.238132122397039,-6.108572423347361,55.02870014391525,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-05,0.7400000095367432,0.7490000128746033,0.7129999995231628,0.7369999885559082,122213,0.0,0.0,0.752400004863739,0.6550250023603439,0.6951916659871737,-2.0467857799415885,14.865845143698344,-5.777782673759919,54.64911853349787,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-08,0.7369999885559082,0.75,0.7020000219345093,0.7099999785423279,76475,0.0,0.0,0.7481000006198884,0.6575000017881394,0.694933332502842,-5.092904965377643,13.77946746545291,-5.386607457708827,51.224457487686976,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-09,0.7089999914169312,0.8100000023841858,0.699999988079071,0.7300000190734863,321030,0.0,0.0,0.751500004529953,0.660325002670288,0.694766665995121,-2.860942824599778,13.807594970804137,-4.95729933667757,53.5466748759061,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-10,0.7300000190734863,0.7549999952316284,0.7200000286102295,0.7549999952316284,70860,0.0,0.0,0.7511000037193298,0.6632250025868416,0.6946749995152156,0.5192373176656152,13.249651444040975,-4.527296498408846,56.344576084721105,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-11,0.7549999952316284,0.7549999952316284,0.7279999852180481,0.753000020980835,95201,0.0,0.0,0.750600004196167,0.6660750031471252,0.6943916663527488,0.31974643901556776,12.690012483529816,-4.077909424569458,56.05371243850162,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-12,0.7400000095367432,0.7400000095367432,0.7020000219345093,0.7289999723434448,208505,0.0,0.0,0.7476999998092652,0.6689000025391578,0.6941916659474373,-2.501006750112428,11.780534754220506,-3.6433257051222676,52.54807846549921,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-15,0.7289999723434448,0.7289999723434448,0.6800000071525574,0.7049999833106995,274930,0.0,0.0,0.7409999966621399,0.6709000021219254,0.6935499990979831,-4.85830141883991,10.448650218885374,-3.2658059268280386,49.23222552692736,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-16,0.7049999833106995,0.7049999833106995,0.6639999747276306,0.6790000200271606,216039,0.0,0.0,0.7292999982833862,0.6718250021338463,0.6929583325982094,-6.897021578859289,8.555054659619419,-3.0497260037446674,45.85636553581554,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-17,0.6890000104904175,0.7020000219345093,0.6359999775886536,0.6499999761581421,298790,0.0,0.0,0.7187999963760376,0.672350001335144,0.6918749993046125,-9.571510929989358,6.908603398327336,-2.822041263102817,42.366800999181656,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-18,0.6510000228881836,1.0720000267028809,0.6510000228881836,0.7390000224113464,7113839,0.0,0.0,0.7186999976634979,0.6754000023007393,0.6914999996622403,2.8245477687274456,6.411014985972445,-2.3282714923159786,53.948912795442546,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-19,0.7390000224113464,0.7390000224113464,0.7009999752044678,0.734000027179718,526035,0.0,0.0,0.7184000015258789,0.6780000030994415,0.6910416667660078,2.1714957712562244,5.958701805567979,-1.8872470783997226,53.30085573116021,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-22,0.734000027179718,0.7570000290870667,0.6890000104904175,0.718999981880188,261088,0.0,0.0,0.7193000018596649,0.6806000024080276,0.6905833333730698,-0.04170999286824171,5.686159170542607,-1.4456374028431525,51.309556717783565,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-23,0.7089999914169312,0.7120000123977661,0.6819999814033508,0.6980000138282776,238346,0.0,0.0,0.7161000013351441,0.6830500021576882,0.6899166668454806,-2.5275781976148117,4.838591475448966,-0.995288999059696,48.57357546915719,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-24,0.7099999785423279,0.8399999737739563,0.675000011920929,0.6919999718666077,1118525,0.0,0.0,0.709799998998642,0.6859000012278557,0.6893500000238418,-2.507752487622697,3.4844726239979638,-0.500471283943839,47.7894825728337,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-25,0.6919999718666077,0.75,0.675000011920929,0.7179999947547913,324429,0.0,0.0,0.7062999963760376,0.688850000500679,0.6892333333690961,1.6565196713557038,2.5332069191660485,-0.05561728515701275,51.44700969349271,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-26,0.7179999947547913,0.7239999771118164,0.6579999923706055,0.6940000057220459,872145,0.0,0.0,0.7027999997138977,0.6918250009417534,0.68909166653951,-1.2521334654858012,1.5863836602037422,0.39665759070482187,48.09755178098276,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-29,0.6930000185966492,0.7490000128746033,0.6700000166893005,0.7379999756813049,425907,0.0,0.0,0.7060999989509582,0.6956249997019768,0.6886999994516373,4.5177703976405645,1.5058399645598108,1.0055176790842704,54.00923364607604,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-04-30,0.7379999756813049,0.7789999842643738,0.7099999785423279,0.7289999723434448,344229,0.0,0.0,0.7110999941825866,0.6989249989390374,0.688358332713445,2.517223781085011,1.7419601905827957,1.5350531436061072,52.687316415648674,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-02,0.7149999737739563,0.7279999852180481,0.6800000071525574,0.6909999847412109,290281,0.0,0.0,0.7151999950408936,0.7013249978423118,0.6853666663169861,-3.383670367377303,1.9783976389362155,2.328437070201041,47.41089067458358,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-03,0.6909999847412109,0.7080000042915344,0.6700000166893005,0.6949999928474426,98397,0.0,0.0,0.7107999920845032,0.7042499974370002,0.6834999993443489,-2.2228474131978,0.9300666909961733,3.0358446397301933,48.00121280673378,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-06,0.6620000004768372,0.6919999718666077,0.6620000004768372,0.6909999847412109,72097,0.0,0.0,0.7064999878406525,0.7072499975562095,0.6823083326220513,-2.1939141353442597,-0.10604591278170292,3.655482974729276,47.427873669904436,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-07,0.6899999976158142,0.7739999890327454,0.6759999990463257,0.7239999771118164,119279,0.0,0.0,0.7069999873638153,0.7103499963879585,0.6812499990065892,2.40452475980782,-0.4715997805557196,4.271559254870222,52.47158645201631,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-08,0.7239999771118164,0.7390000224113464,0.6909999847412109,0.7250000238418579,19878,0.0,0.0,0.7096999883651733,0.7131249964237213,0.6800416658322016,2.155845530155483,-0.4802815881821784,4.864897586978576,52.61993441938833,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-10,0.7390000224113464,0.7390000224113464,0.6549999713897705,0.6579999923706055,966454,0.0,0.0,0.7062999904155731,0.7142999961972236,0.6784499992926916,-6.83845373076515,-1.1199784158253918,5.284103020400465,42.94804945691384,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-13,0.699999988079071,0.699999988079071,0.6600000262260437,0.6899999976158142,175131,0.0,0.0,0.7034999907016755,0.7162749961018562,0.6773666659990947,-1.918975588385761,-1.78353362461421,5.744057399897726,47.87591645982386,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-14,0.6899999976158142,0.6990000009536743,0.6610000133514404,0.6990000009536743,169189,0.0,0.0,0.7039999902248383,0.7184499964118004,0.6761999994516372,-0.7102257586064885,-2.0112751421992754,6.248150990006761,49.20480458612186,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-15,0.6990000009536743,0.699999988079071,0.6850000023841858,0.699999988079071,26357,0.0,0.0,0.7001999914646149,0.7204999968409538,0.6753583326935768,-0.028563751496979352,-2.817488614204675,6.684105601738184,49.35928954450245,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-16,0.699999988079071,0.7889999747276306,0.6850000023841858,0.75,710537,0.0,0.0,0.7022999942302703,0.7240499973297119,0.6750583325823148,6.791970121259856,-3.003936631400496,7.257397232619614,56.48549014479711,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-17,0.7509999871253967,0.7860000133514404,0.7149999737739563,0.7390000224113464,557014,0.0,0.0,0.707099997997284,0.7272499978542328,0.6746166661381722,4.5113879938357755,-2.770711573241924,7.801961374206626,54.66302881831564,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-20,0.7289999723434448,0.7300000190734863,0.7039999961853027,0.7149999737739563,244857,0.0,0.0,0.7090999960899353,0.7226249977946282,0.6740833327174187,0.8320374723669659,-1.8716487453339776,7.2011371177988375,50.811044198468736,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-21,0.7039999961853027,0.7300000190734863,0.7039999961853027,0.7300000190734863,101715,0.0,0.0,0.7129999995231628,0.7225749984383583,0.6738249997297923,2.3842944686806016,-1.3251218123916653,7.234815972710279,53.03844540185212,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-22,0.7300000190734863,0.7300000190734863,0.699999988079071,0.7250000238418579,71391,0.0,0.0,0.713100004196167,0.7218749985098839,0.6732916668057441,1.6687729036132903,-1.2155836303834422,7.215792813036086,52.190084683632286,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-23,0.7250000238418579,0.7300000190734863,0.7049999833106995,0.7099999785423279,57558,0.0,0.0,0.711599999666214,0.7222249984741211,0.6726000001033147,-0.22484838738570026,-1.4711480259413705,7.378084799759713,49.62558265070498,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-24,0.7099999785423279,0.75,0.6840000152587891,0.7089999914169312,964490,0.0,0.0,0.7166999995708465,0.7209749981760979,0.6719249998529752,-1.0743697723630607,-0.592946858915517,7.299921618313865,49.45112991400033,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-27,0.7089999914169312,0.7089999914169312,0.671999990940094,0.6880000233650208,89595,0.0,0.0,0.7165000021457673,0.7192249983549118,0.6709916666150093,-3.9776662519741866,-0.37887951828391286,7.188365242034676,45.80918290748807,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-28,0.7089999914169312,0.7089999914169312,0.6759999990463257,0.6930000185966492,118148,0.0,0.0,0.7159000039100647,0.7175999984145165,0.6703250000874201,-3.1987687090852917,-0.2369000150791258,7.05254888612703,46.81355356632157,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-29,0.6949999928474426,0.703000009059906,0.6729999780654907,0.6800000071525574,118436,0.0,0.0,0.7139000058174133,0.7152999982237815,0.6697083334128062,-4.748563998965169,-0.19572101353902785,6.807689636866554,44.50400933811637,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-30,0.6800000071525574,0.7160000205039978,0.6800000071525574,0.7049999833106995,187029,0.0,0.0,0.7094000041484833,0.7130249977111817,0.6696666667858759,-0.620245392169864,-0.508396420088311,6.474613875199708,49.64855639523866,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-05-31,0.7049999833106995,0.7300000190734863,0.7049999833106995,0.7170000076293945,167011,0.0,0.0,0.707200002670288,0.7120749980211258,0.6698916668693224,1.3857473023335753,-0.6846182444806418,6.297037750737122,51.9510409929517,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-03,0.7170000076293945,0.7490000128746033,0.7039999961853027,0.7300000190734863,218558,0.0,0.0,0.7087000072002411,0.7118249982595444,0.6702416668335597,3.0055046785440496,-0.4390111427589787,6.204229531481968,54.38460375235915,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-04,0.7289999723434448,0.7289999723434448,0.6949999928474426,0.7049999833106995,160106,0.0,0.0,0.7062000036239624,0.7110249981284141,0.6712166666984558,-0.1699264099553767,-0.6785970278333752,5.930772193986986,49.22167066265178,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-05,0.7089999914169312,0.7170000076293945,0.699999988079071,0.7160000205039978,21780,0.0,0.0,0.7053000032901764,0.7111749991774559,0.6724333335955938,1.5170873619603802,-0.8260970779448771,5.7614136073096,51.40755648704634,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-07,0.7160000205039978,0.7200000286102295,0.7009999752044678,0.7200000286102295,85664,0.0,0.0,0.7063000082969666,0.7109249994158745,0.6736166670918464,1.9396885391940515,-0.6505596402866675,5.538510869259884,52.21313706698902,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-10,0.7200000286102295,0.7269999980926514,0.6919999718666077,0.7179999947547913,69259,0.0,0.0,0.7072000086307526,0.7099999994039535,0.6747916668653489,1.5271473405308742,-0.39436489796500285,5.217659652224234,51.75115886081044,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-11,0.7129999995231628,0.7179999947547913,0.6990000009536743,0.7170000076293945,70561,0.0,0.0,0.7101000070571899,0.7090999990701675,0.6760916670163473,0.9716941985115236,0.14102495957321584,4.882227316820656,51.505778724475874,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-12,0.7009999752044678,0.7120000123977661,0.6800000071525574,0.6899999976158142,163432,0.0,0.0,0.7098000049591064,0.7081249997019767,0.6772166669368744,-2.789519189202171,0.2365409013711789,4.564024229483909,45.265034546857024,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-13,0.6899999976158142,0.6980000138282776,0.6600000262260437,0.6700000166893005,310014,0.0,0.0,0.7088000059127808,0.7072500005364418,0.6781000003218651,-5.4740390660006115,0.2191594733352164,4.298776021344999,41.27549267153085,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-14,0.6800000071525574,0.6890000104904175,0.652999997138977,0.6880000233650208,40993,0.0,0.0,0.7071000099182129,0.7074750006198883,0.6790583337346713,-2.7011718689413295,-0.053004092207766106,4.184716610269936,45.89725139005143,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-17,0.699999988079071,0.7020000219345093,0.6639999747276306,0.6700000166893005,179223,0.0,0.0,0.7024000108242034,0.7079750016331673,0.679925000667572,-4.612755358144773,-0.7874558841913021,4.125455151385066,42.311113189107616,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-18,0.6700000166893005,0.7020000219345093,0.6620000004768372,0.699999988079071,65700,0.0,0.0,0.699400007724762,0.7070000007748604,0.6811166673898696,0.08578500824741125,-1.074963655129976,3.8001321395024905,49.40638322414412,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-19,0.699999988079071,0.699999988079071,0.656000018119812,0.6959999799728394,156851,0.0,0.0,0.698500007390976,0.7060499995946884,0.6822583337624868,-0.3579137282295317,-1.0693282640105592,3.487193142954579,48.548986825002864,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-20,0.6959999799728394,0.7099999785423279,0.6520000100135803,0.6899999976158142,119166,0.0,0.0,0.6959000051021575,0.7053249999880791,0.682916667064031,-0.8478240326319905,-1.3362626996180227,3.28126900466277,47.22511659381705,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-24,0.6899999976158142,0.699999988079071,0.6899999976158142,0.6899999976158142,38597,0.0,0.0,0.6929000020027161,0.7051249995827675,0.6836666668454806,-0.4185314444392927,-1.7337348111732205,3.1387127350084545,47.22511659381705,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-25,0.699999988079071,0.7089999914169312,0.6909999847412109,0.7059999704360962,66959,0.0,0.0,0.6916999995708466,0.7054749995470047,0.6834666664401691,2.0673660364495823,-1.9525851355474217,3.2201033623871993,51.32968973335036,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-26,0.7059999704360962,0.7879999876022339,0.6840000152587891,0.734000027179718,199178,0.0,0.0,0.6934000015258789,0.7058750003576278,0.6836333334445953,5.855209917002556,-1.767309909747274,3.2534497405157756,57.55163308623633,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-27,0.7419999837875366,0.7419999837875366,0.6830000281333923,0.6880000233650208,152244,0.0,0.0,0.6932000041007995,0.7057250007987023,0.6835333337386449,-0.750141475045725,-1.7747701560420301,3.246610803701134,46.93588530668528,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-06-28,0.699999988079071,0.699999988079071,0.671999990940094,0.6899999976158142,56361,0.0,0.0,0.6952000021934509,0.704525001347065,0.6830916672945022,-0.7479868471274413,-1.3235866911443162,3.1376951408956617,47.39025603783373,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-01,0.6899999976158142,0.7350000143051147,0.6899999976158142,0.7260000109672546,280503,0.0,0.0,0.6990000009536743,0.7044500023126602,0.6831166674693425,3.8626623714940065,-0.7736533950023287,3.1229416378242725,54.87962263174127,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-02,0.7260000109672546,0.7260000109672546,0.671999990940094,0.6909999847412109,264948,0.0,0.0,0.7010999977588653,0.7044500023126602,0.6833083341519038,-1.4405952146541259,-0.4755489449637348,3.0940158496671324,47.76090395807865,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-03,0.6949999928474426,0.7120000123977661,0.6909999847412109,0.6919999718666077,82068,0.0,0.0,0.7002999961376191,0.7043750017881394,0.6834500004847844,-1.1852098124787542,-0.578527863733869,3.0616725859261744,47.96857081568072,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-04,0.6919999718666077,0.699999988079071,0.6729999780654907,0.6880000233650208,135690,0.0,0.0,0.6995000004768371,0.7043000027537346,0.6838000004490217,-1.6440281778380341,-0.6815280786781202,2.997952952800743,47.160965990871105,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-05,0.6949999928474426,1.2960000038146973,0.6949999928474426,0.9390000104904175,11719911,0.0,0.0,0.7244000017642975,0.7096750035881996,0.685733333726724,29.624517973972296,2.074893169640561,3.4913965362250803,75.28285269094637,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-08,0.9399999976158142,0.9789999723434448,0.8899999856948853,0.9679999947547913,1258673,0.0,0.0,0.7522000014781952,0.715750002861023,0.6878833338618279,28.689177459786492,5.092560037928457,4.051074888346191,76.81799727179373,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-09,0.9700000286102295,1.2979999780654907,0.9700000286102295,1.2640000581741333,7222009,0.0,0.0,0.8080000102519989,0.7309000045061111,0.6925166676441828,56.43564877925154,10.548639385764714,5.5425867210534445,86.22332684480568,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-10,1.2740000486373901,2.384999990463257,1.2740000486373901,2.0450000762939453,30108293,0.0,0.0,0.9391000151634217,0.7647750064730644,0.7037333349386851,117.76169132933892,22.79428684447954,8.67397755709523,93.6006819170177,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-11,2.194999933242798,2.9800000190734863,2.055000066757202,2.765000104904175,29419496,0.0,0.0,1.146800023317337,0.8164250090718269,0.7210083360473315,141.10568963068962,40.466057577180926,13.233782226095048,95.82193377507328,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-12,2.9000000953674316,3.2200000286102295,2.309999942779541,2.515000104904175,18261196,0.0,0.0,1.3293000340461731,0.8618000119924545,0.736441670358181,89.19732494468713,54.24692684476452,17.02216844591417,84.81359565899183,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-15,2.3350000381469727,2.390000104904175,1.9900000095367432,2.009999990463257,6786203,0.0,0.0,1.4577000319957734,0.893300011754036,0.7473916704456012,37.88845073367501,63.181463429459924,19.52233976884476,67.85547017659138,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-16,1.9839999675750732,2.119999885559082,1.656000018119812,1.9620000123977661,10341445,0.0,0.0,1.5848000347614288,0.9238750115036964,0.7580750038226446,23.801108617032547,71.53835908842395,21.87118779078509,66.49454995923793,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-17,2.0,2.2100000381469727,1.9739999771118164,2.005000114440918,4475631,0.0,0.0,1.7161000490188598,0.9561250150203705,0.7690333381295205,16.834686624898705,79.48490229411034,24.328162072388608,67.13054457821973,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-18,2.005000114440918,2.0450000762939453,1.7999999523162842,1.940000057220459,2142828,0.0,0.0,1.8413000524044036,0.9863750159740448,0.7793000052372615,5.360343344756388,86.67342771107405,26.571924720280006,65.11834849527017,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-19,1.940000057220459,1.9859999418258667,1.899999976158142,1.9140000343322754,929824,0.0,0.0,1.9388000547885895,1.0161000162363052,0.789508338769277,-1.279142756111505,90.80799368255303,28.700352654951068,64.2882560743187,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-22,1.9119999408721924,1.9279999732971191,1.7000000476837158,1.722000002861023,1300673,0.0,0.0,2.0142000555992126,1.0414000168442725,0.798258338868618,-14.507002515758636,93.41271586520527,30.45902136396877,58.37085039158502,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-23,1.722000002861023,1.722000002861023,1.565999984741211,1.6799999475479126,1272360,0.0,0.0,2.0558000445365905,1.0656750157475472,0.8066500052809715,-18.279992647504255,92.91059789878744,32.11120173195218,57.13201811891897,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-24,1.6799999475479126,1.694000005722046,1.5820000171661377,1.6080000400543213,449791,0.0,0.0,2.012100040912628,1.0886750161647796,0.8145666723450025,-20.08349449041407,84.82099901593415,33.65081743777518,54.977891013146916,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-25,1.5800000429153442,2.059999942779541,1.5499999523162842,1.9459999799728394,3314415,0.0,0.0,1.9302000284194947,1.1200000151991845,0.825466672082742,0.8185655020574294,72.33928591297578,35.68082795799651,62.18589410677936,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-26,1.9759999513626099,2.2049999237060547,1.968000054359436,2.009999990463257,3617924,0.0,0.0,1.8797000169754028,1.153250014781952,0.8369083384672801,6.9319557541696355,62.991545014703746,37.79884388462688,63.38136601231081,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-29,2.015000104904175,2.075000047683716,1.850000023841858,1.9500000476837158,1037537,0.0,0.0,1.8737000226974487,1.1843750163912774,0.8479833389321964,4.072157979505317,58.20158284041697,39.669609297120694,61.42090931322862,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-30,1.9520000219345093,2.365000009536743,1.9520000219345093,2.25,5165464,0.0,0.0,1.9025000214576722,1.2227000162005424,0.8614916721979777,18.26543887637266,55.598265825624374,41.92824558373166,66.92896670528509,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-07-31,2.315000057220459,2.930000066757202,2.2899999618530273,2.8499999046325684,11048865,0.0,0.0,1.9870000004768371,1.2757000133395195,0.8800000046690305,43.4323051811087,55.75762167433713,44.96590983761557,74.70688624288937,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-01,2.940000057220459,3.0850000381469727,2.4000000953674316,2.4649999141693115,8283788,0.0,0.0,2.0394999861717222,1.3197000116109847,0.8952500040332476,20.8629532180719,54.54269669074739,47.41133824803356,64.26281867506873,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-02,2.3550000190734863,2.7950000762939453,2.1500000953674316,2.319999933242798,4145122,0.0,0.0,2.0800999760627747,1.359800009429455,0.9094916701316833,11.533097444388568,52.97102232963974,49.51209055411936,60.814494790654614,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-05,2.174999952316284,2.9000000953674316,2.005000114440918,2.6700000762939453,6206740,0.0,0.0,2.1748999834060667,1.4085500106215476,0.9266000042359034,22.764269468268257,54.407011963057926,52.01273518049159,65.61127010190177,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-06,2.799999952316284,3.0999999046325684,2.7699999809265137,3.0999999046325684,7247480,0.0,0.0,2.3168999791145324,1.468100008368492,0.9471083367864291,33.799470524287344,57.816222730583355,55.008667049622375,70.40455785692275,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-07,3.200000047683716,3.3350000381469727,2.9600000381469727,3.0799999237060547,6198982,0.0,0.0,2.4640999674797057,1.5271750062704086,0.9674500028292338,24.99492570734842,61.350202652766626,57.8557033236138,69.91641995444178,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-08,2.9600000381469727,3.1649999618530273,2.8299999237060547,3.065000057220459,3578723,0.0,0.0,2.5759999752044678,1.5865500077605248,0.9878583366672198,18.982922621230898,62.364877413513675,60.60501277067083,69.52707173839016,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-09,3.1050000190734863,3.7799999713897705,3.1050000190734863,3.75,7241303,0.0,0.0,2.749999976158142,1.6635500073432923,1.0139000033338865,36.36363754587726,65.3091259065859,64.07436649307023,76.07849112844706,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-12,3.859999895095825,4.75,3.765000104904175,4.539999961853027,15126559,0.0,0.0,3.008999967575073,1.7598500058054924,1.046383336186409,50.880691617679666,70.98047888449666,68.1840626609503,81.11985235767816,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-13,4.539999961853027,4.885000228881836,3.1050000190734863,3.8299999237060547,17711655,0.0,0.0,3.1669999599456786,1.8388500034809112,1.0730583354830743,20.934637579589612,72.2272047176552,71.36533426704051,67.37673660013266,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-14,3.8299999237060547,3.8399999141693115,2.9749999046325684,3.1500000953674316,8021639,0.0,0.0,3.196999979019165,1.9001000061631204,1.09416666974624,-1.470124615582671,68.25430075519448,73.65727349415543,57.354578296110574,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-15,3.059999942779541,3.884999990463257,2.8399999141693115,3.434999942779541,8693410,0.0,0.0,3.293999981880188,1.9685750052332878,1.1175416693091393,4.280508854735063,67.32915805206162,76.1522687964069,60.03759519920305,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-16,3.494999885559082,3.6700000762939453,3.109999895095825,3.184999942779541,3200276,0.0,0.0,3.380499982833862,2.030950003862381,1.1389583354194959,-5.783169384619673,66.44919748910412,78.31644413176456,56.66952867716291,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-19,3.2300000190734863,3.3399999141693115,3.0199999809265137,3.109999895095825,1119023,0.0,0.0,3.4244999647140504,2.091450001299381,1.159875001013279,-9.183824583408525,63.73807466525467,80.31684444205352,55.66071179281745,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-20,3.109999895095825,3.109999895095825,2.5999999046325684,2.875,3173450,0.0,0.0,3.4019999742507934,2.145675002038479,1.1790166676044465,-15.490887073473658,58.55150342054386,81.98852153618077,52.50666598346769,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-21,2.7750000953674316,3.109999895095825,2.4000000953674316,2.680000066757202,3004380,0.0,0.0,3.361999988555908,2.1943250030279158,1.1963500012954076,-20.285542061873947,53.21340202188534,83.4183140930247,49.976014508623685,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-22,2.680000066757202,2.680000066757202,2.369999885559082,2.4700000286102295,2520534,0.0,0.0,3.3024999856948853,2.238875003159046,1.2121416682998338,-25.208174434238124,47.50711768343778,84.704070630566,47.33039365180848,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-23,2.4600000381469727,2.515000104904175,2.2799999713897705,2.4749999046325684,1370633,0.0,0.0,3.174999976158142,2.283500000834465,1.227883333961169,-22.047246512820372,39.04094482145364,85.9704369036317,47.40178761917484,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-26,2.5,2.5999999046325684,2.299999952316284,2.424999952316284,2051268,0.0,0.0,2.963499975204468,2.325974999368191,1.243116666873296,-18.171082415852887,27.408935006156526,87.10834319505302,46.71976754888977,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-27,2.4200000762939453,2.8550000190734863,2.3499999046325684,2.734999895095825,2013909,0.0,0.0,2.853999972343445,2.377074997127056,1.2609499990940094,-4.1695892922489275,20.063522429574274,88.51461190649754,51.3896690436375,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-28,2.7799999713897705,3.4600000381469727,2.6600000858306885,3.450000047683716,4444352,0.0,0.0,2.883999967575073,2.446024999022484,1.2848833327492077,19.625523109299728,17.90558022618817,90.36942395297734,60.08041131588689,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-29,3.5299999713897705,3.990000009536743,2.9700000286102295,3.190000057220459,6178315,0.0,0.0,2.859499979019165,2.50857499986887,1.306708333392938,11.557967498732374,13.989016838987828,91.97665888876831,56.14922235362704,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-08-30,3.200000047683716,3.369999885559082,2.865000009536743,2.9000000953674316,2672980,0.0,0.0,2.830999994277954,2.557600001990795,1.325875000655651,2.4373048826895563,10.689708792397125,92.89902899791086,52.05769683200524,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-02,2.9049999713897705,3.3450000286102295,2.7300000190734863,2.7750000953674316,4238163,0.0,0.0,2.7975000143051147,2.6027750045061113,1.3438833345969519,-0.8042866424532255,7.481438444040744,93.67566644367366,50.354455534094384,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-03,2.7750000953674316,2.950000047683716,2.5999999046325684,2.640000104904175,1886757,0.0,0.0,2.7740000247955323,2.6371750056743624,1.3607916687925656,-4.8305666436046435,5.188317757705348,93.79711576382117,48.50851536699928,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-04,2.5999999046325684,2.7699999809265137,2.4600000381469727,2.680000066757202,1557484,0.0,0.0,2.7740000247955323,2.6530500054359436,1.3780333360036214,-3.3886069646037145,4.558904623424708,92.52437050107557,49.10386899962208,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-05,2.6500000953674316,2.7950000762939453,2.509999990463257,2.7149999141693115,967090,0.0,0.0,2.7985000133514406,2.651800000667572,1.395558335383733,-2.9837448198590732,5.5320918865275654,90.01713747339794,49.65241055465314,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-06,2.734999895095825,2.930000066757202,2.6449999809265137,2.75,1389257,0.0,0.0,2.8260000228881834,2.6576749980449677,1.413325002292792,-2.6893143054723363,6.333544356139807,88.04415076033514,50.23007993579301,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-09,2.75,2.859999895095825,2.549999952316284,2.640000104904175,961272,0.0,0.0,2.847500038146973,2.673425000905991,1.4302583366632462,-7.28709150001732,6.511311788510625,86.9190294071642,48.352379267637176,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-10,2.634999990463257,2.700000047683716,2.5,2.575000047683716,1073481,0.0,0.0,2.8315000534057617,2.688750001788139,1.4466250037153563,-9.0588027859482,5.309160447147834,85.86364779280342,47.228871166334045,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-11,2.565000057220459,3.0799999237060547,2.5199999809265137,2.8949999809265137,3501911,0.0,0.0,2.7760000467300414,2.710999998450279,1.4632500037550926,4.286741073244826,2.397641029764629,85.27250924265333,53.01678340891129,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-12,2.9600000381469727,3.1500000953674316,2.555000066757202,2.569999933242798,3195620,0.0,0.0,2.714000034332275,2.7267499953508376,1.4785666699210802,-5.305825323060678,-0.4675881925479542,84.4184676160988,47.33801898217363,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-13,2.569999933242798,2.7249999046325684,2.5,2.694999933242798,1568110,0.0,0.0,2.693500018119812,2.7462749928236008,1.4947500025232634,0.05568647161297446,-1.9216930147817328,83.72804737833471,49.57517439269198,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-16,2.690000057220459,2.740000009536743,2.569999933242798,2.640000104904175,969882,0.0,0.0,2.6800000190734865,2.7692249953746795,1.5109500035643577,-1.4925341001728885,-3.2220197510213766,83.27707659697732,48.596937873368596,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-17,2.640000104904175,2.8550000190734863,2.5799999237060547,2.700000047683716,1308462,0.0,0.0,2.6860000133514403,2.794724997878075,1.5271250039339066,0.5212224222890833,-3.890364333134212,83.00564725734984,49.76157288169903,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-18,2.7049999237060547,2.815000057220459,2.6600000858306885,2.6700000762939453,643748,0.0,0.0,2.685000014305115,2.821274998784065,1.543058337767919,-0.5586569061919218,-4.830262364983314,82.83657394736777,49.16180479253005,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-19,2.700000047683716,2.75,2.549999952316284,2.6700000762939453,1750801,0.0,0.0,2.680500030517578,2.839375001192093,1.5589916716019312,-0.3917162508520985,-5.5954204924609225,82.12893968025583,49.16180479253005,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-20,2.619999885559082,2.6649999618530273,2.549999952316284,2.609999895095825,456077,0.0,0.0,2.6665000200271605,2.854374998807907,1.5743083372712134,-2.118887099455554,-6.582000573127571,81.30978101503699,47.824768425952506,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-23,2.6050000190734863,2.7899999618530273,2.505000114440918,2.640000104904175,965933,0.0,0.0,2.6665000200271605,2.8716250002384185,1.5896750047802926,-0.9938089227059423,-7.143167377155005,80.64226911810209,48.57781586267196,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-24,2.700000047683716,2.7899999618530273,2.5799999237060547,2.625,764608,0.0,0.0,2.671500015258789,2.8810000002384184,1.6052583381533623,-1.7405957324796952,-7.271780109763702,79.47267002223633,48.20319799372077,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-25,2.549999952316284,2.740000009536743,2.5199999809265137,2.615000009536743,563678,0.0,0.0,2.643500018119812,2.875125002861023,1.6208833381533623,-1.07811645120923,-8.056170932071558,77.38013188145864,47.937787272942714,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-26,2.615000009536743,2.6700000762939453,2.555000066757202,2.6050000190734863,462238,0.0,0.0,2.647000026702881,2.8786250054836273,1.636450005074342,-1.5867021989308467,-8.046375555673734,75.90668804775706,47.65520970838978,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-27,2.6050000190734863,2.9100000858306885,2.5,2.865000009536743,2045557,0.0,0.0,2.6640000343322754,2.892250007390976,1.6544083386659623,7.5450440170451385,-7.8917788045784825,74.82080691899507,55.07081585767574,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-09-30,2.950000047683716,2.994999885559082,2.7049999237060547,2.75,1006452,0.0,0.0,2.675000023841858,2.8942500054836273,1.6712416718403498,2.8037374014833203,-7.5753642990883465,73.17962172978349,51.58949767374709,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-01,2.759999990463257,2.7950000762939453,2.6600000858306885,2.6600000858306885,456392,0.0,0.0,2.671000027656555,2.8832500100135805,1.687116672595342,-0.41182859273564243,-7.36148379848703,70.8980805446129,48.979925969049255,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-02,2.6600000858306885,2.7149999141693115,2.619999885559082,2.6600000858306885,258573,0.0,0.0,2.6700000286102297,2.872750014066696,1.703008339802424,-0.37452968810439663,-7.057696787526995,68.68678484569139,48.979925969049255,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-03,2.6649999618530273,2.700000047683716,2.565000057220459,2.619999885559082,326204,0.0,0.0,2.665000009536743,2.8616250097751617,1.7187666724125543,-1.6885599931192243,-6.8710959530601645,66.49293098977938,47.735305109029014,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-04,2.5999999046325684,2.6649999618530273,2.549999952316284,2.630000114440918,453955,0.0,0.0,2.6670000314712525,2.8336250126361846,1.734808340171973,-1.3873234568326394,-5.880276339384693,63.339369947649956,48.09044439714429,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-07,2.630000114440918,2.6600000858306885,2.555000066757202,2.609999895095825,308238,0.0,0.0,2.6640000104904176,2.785375010967255,1.750900005797545,-2.027031350673736,-4.357582013155504,59.08247197123633,47.39678120315597,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-08,2.609999895095825,2.6600000858306885,2.565000057220459,2.619999885559082,288080,0.0,0.0,2.6634999990463255,2.7551250100135802,1.7673166717092197,-1.6331936738433952,-3.3256208206248723,55.893114919185614,47.802188597241525,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-09,2.640000104904175,2.8499999046325684,2.619999885559082,2.6600000858306885,1314143,0.0,0.0,2.66800000667572,2.7428750097751617,1.7833250055710475,-0.29984710738435894,-2.7298000394695077,53.80679355734441,49.479427295963795,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-10,2.7950000762939453,2.8299999237060547,2.674999952316284,2.690000057220459,490701,0.0,0.0,2.6765000104904173,2.7242500126361846,1.799625005821387,0.5043918056091491,-1.7527760640280179,51.37875967625707,50.7574153053125,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-11,2.690000057220459,3.0350000858306885,2.690000057220459,3.0,1396633,0.0,0.0,2.6900000095367433,2.719625014066696,1.8186333393057188,11.52416317339133,-1.0893047525568216,49.542238959775126,61.57436915242479,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-14,3.055000066757202,3.115000009536743,2.7799999713897705,2.875,1227687,0.0,0.0,2.702500009536743,2.7137500166893007,1.8367750058571497,6.38297834799366,-0.414555765393687,47.745369358556886,56.2123432411052,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-15,2.875,3.3350000381469727,2.805000066757202,3.325000047683716,2188018,0.0,0.0,2.769000005722046,2.7250000178813933,1.8587166731556257,20.079452539281842,1.6146784422725036,46.60653004500357,67.26427379135438,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-16,3.315000057220459,3.509999990463257,3.1500000953674316,3.319999933242798,2211162,0.0,0.0,2.834999990463257,2.741000014543533,1.880400005976359,17.10758181344081,3.4294044298054467,45.766858425440454,67.06173263741788,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-17,3.325000047683716,4.050000190734863,3.240000009536743,4.034999847412109,4347180,0.0,0.0,2.9764999866485597,2.78012501001358,1.9082416713237762,35.56189704389636,7.063530450165634,45.69040451176004,77.49661243537898,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-18,4.034999847412109,4.050000190734863,3.559999942779541,3.950000047683716,4039084,0.0,0.0,3.1084999799728394,2.817000013589859,1.935008338590463,27.070936887000684,10.347886580643133,45.58076869280439,74.475969027708,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-21,3.950000047683716,4.0,3.375,3.450000047683716,3242716,0.0,0.0,3.1924999952316284,2.8426250159740447,1.9576833392182986,8.06578082495517,12.30816506895816,45.20351473742953,59.72801957657755,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-22,3.4649999141693115,4.079999923706055,3.384999990463257,3.9800000190734863,3708630,0.0,0.0,3.328500008583069,2.873750019073486,1.9850916728377341,19.57338166773083,15.824270952286826,44.76661498284331,67.153089252017,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-23,3.9800000190734863,4.349999904632568,3.5450000762939453,3.609999895095825,7019466,0.0,0.0,3.4234999895095823,2.877750015258789,2.009383338689804,5.447638561639343,18.964467773678916,43.215580613662006,58.97790425472974,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-24,3.6600000858306885,3.8450000286102295,3.549999952316284,3.6600000858306885,1996375,0.0,0.0,3.5204999923706053,2.8895000159740447,2.034125006198883,3.9625079892742097,21.837687243751468,42.051250890110175,59.69203372252723,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-25,3.7049999237060547,4.050000190734863,3.6649999618530273,3.8299999237060547,2155169,0.0,0.0,3.603499984741211,2.9127500116825105,2.0600083390871684,6.285554042568145,23.714701580576023,41.39505925365376,62.10735841757724,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-28,3.865000009536743,4.045000076293945,3.7100000381469727,3.7750000953674316,1115686,0.0,0.0,3.6934999942779543,2.9377500116825104,2.0854250063498814,2.2065818658654117,25.725469478004026,40.870566083047656,60.83721870055662,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-29,3.7750000953674316,3.875,3.619999885559082,3.6500000953674316,1039477,0.0,0.0,3.7259999990463255,2.963000011444092,2.110358340541522,-2.0397182957151405,25.750927595520544,40.40269628729407,57.937209505782626,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-30,3.6549999713897705,3.7750000953674316,3.5399999618530273,3.7249999046325684,840727,0.0,0.0,3.7664999961853027,2.989125007390976,2.135650006433328,-1.1018210963697201,26.006774118585625,39.963242965218136,59.1940729691869,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-10-31,3.7249999046325684,3.859999895095825,3.609999895095825,3.7799999713897705,1076774,0.0,0.0,3.741000008583069,3.0157500088214872,2.161325006186962,1.0425010082123203,24.048744015257395,39.5324627341407,60.13481711114099,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-01,3.8450000286102295,3.890000104904175,3.615000009536743,3.615000009536743,942757,0.0,0.0,3.7075000047683715,3.037375009059906,2.1856166730324427,-2.494942551926101,22.062636115382897,38.97107605999765,55.96631257648752,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-04,3.6700000762939453,3.7899999618530273,3.619999885559082,3.6700000762939453,826689,0.0,0.0,3.7295000076293947,3.06312500834465,2.209950007001559,-1.5953862773490035,21.75474384719485,38.60607699903002,57.035438172142584,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-05,3.6700000762939453,3.7100000381469727,3.450000047683716,3.5,923147,0.0,0.0,3.6815000057220457,3.0862500071525574,2.232958340148131,-4.930055831588909,19.287160702793457,38.21350589764341,52.770566107202185,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-06,3.5,3.5799999237060547,3.2249999046325684,3.3299999237060547,1016027,0.0,0.0,3.6535000085830687,3.097125005722046,2.254750006397565,-8.854525362447625,17.964241089174653,37.36001760436188,48.83776746119687,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-07,3.3350000381469727,3.440000057220459,3.190000057220459,3.255000114440918,816964,0.0,0.0,3.613000011444092,3.114250010251999,2.2757916738589605,-9.908660278694096,16.015091901749244,36.84249072637221,47.16763920268738,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-08,3.2249999046325684,3.3299999237060547,3.0999999046325684,3.2699999809265137,834901,0.0,0.0,3.557000017166138,3.128625011444092,2.297000006834666,-8.068598112301306,13.692117276922207,36.20483248301901,47.55393399792066,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-11,3.174999952316284,3.200000047683716,2.8499999046325684,3.1500000953674316,1648483,0.0,0.0,3.494500017166138,3.1413750112056733,2.3173333411415418,-9.858346547615076,11.241096803177713,35.55991084382363,44.73585780887864,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-12,3.1449999809265137,3.434999942779541,2.9200000762939453,3.009999990463257,1069543,0.0,0.0,3.4305000066757203,3.1491250097751617,2.3365083411335945,-12.257688832361884,8.935021506835891,34.77910411598673,41.63582914095555,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-13,2.9700000286102295,2.9700000286102295,2.75,2.865000009536743,858065,0.0,0.0,3.344500017166138,3.1540000081062316,2.3546500076850254,-14.336971301189728,6.039949542495053,33.94772037510098,38.648603591041635,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-14,2.819999933242798,2.944999933242798,2.700000047683716,2.865000009536743,507729,0.0,0.0,3.253000020980835,3.1588750064373015,2.3727500076095263,-11.92745185802683,2.9797005057725046,33.13138747472905,38.648603591041635,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-15,2.9000000953674316,2.9800000190734863,2.759999990463257,2.8499999046325684,450197,0.0,0.0,3.1765000104904173,3.1648750066757203,2.3908333400885264,-10.278611829988343,0.3673132047924862,32.37539202789154,38.31876006608343,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-18,2.8450000286102295,2.9000000953674316,2.740000009536743,2.884999990463257,376226,0.0,0.0,3.098000001907349,3.1710000038146973,2.409000006814798,-6.875403851289671,-2.302112955519704,31.631382102294918,39.613765531474336,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-19,2.869999885559082,3.3299999237060547,2.869999885559082,3.2750000953674316,1086297,0.0,0.0,3.075500011444092,3.187250006198883,2.4303166742126145,6.486752826564459,-3.506157174286564,31.145461001764435,51.76590931127197,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-20,3.384999990463257,3.5899999141693115,3.2049999237060547,3.319999933242798,1408544,0.0,0.0,3.074500012397766,3.2048750042915346,2.451900006830692,7.985035610833173,-4.068021115306779,30.70985747229277,52.94263031976589,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-21,3.325000047683716,3.4800000190734863,2.825000047683716,2.994999885559082,1900351,0.0,0.0,3.0484999895095823,3.2146250009536743,2.470983339349429,-1.7549648723832527,-5.167788199084127,30.094968661344133,44.4990390352734,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-22,3.0,3.015000104904175,2.940000057220459,2.940000057220459,496869,0.0,0.0,3.015499997138977,3.216500002145767,2.489516672988733,-2.5037287345431984,-6.249028598560565,29.201785914704114,43.24216512288318,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-25,2.950000047683716,3.009999990463257,2.9000000953674316,3.0,528557,0.0,0.0,3.000499987602234,3.222750002145767,2.508516672750314,-0.016663476230618122,-6.896284675992711,28.47233734398004,45.06506932508636,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-26,2.994999885559082,3.0250000953674316,2.9100000858306885,2.950000047683716,399259,0.0,0.0,2.99449999332428,3.230000001192093,2.5271166731913883,-1.4860559605867116,-7.29102191272128,27.81364768224426,43.80254202397276,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-27,2.9800000190734863,3.0,2.815000057220459,2.8550000190734863,476598,0.0,0.0,2.993499994277954,3.234874999523163,2.5449333399534226,-4.626690344720532,-7.461648604066269,27.110402018717224,41.42772243926762,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-28,2.825000047683716,2.934999942779541,2.805000066757202,2.880000114440918,323423,0.0,0.0,2.9950000047683716,3.241375005245209,2.563183340926965,-3.839729220179,-7.60094096110916,26.458960367344563,42.31406952625524,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-11-29,2.819999933242798,2.990000009536743,2.755000114440918,2.990000009536743,2313049,0.0,0.0,3.0090000152587892,3.2503750026226044,2.582516674200694,-0.6314392032467963,-7.426065828375458,25.860755715299184,46.17366517030482,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-02,2.8499999046325684,2.950000047683716,2.799999952316284,2.8499999046325684,503465,0.0,0.0,3.00550000667572,3.2563750028610228,2.600533339877923,-5.173851329155211,-7.704118719892093,25.219506050012296,42.29500476222889,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-03,2.8299999237060547,2.8299999237060547,2.6649999618530273,2.690000057220459,657405,0.0,0.0,2.947000002861023,3.2581250071525574,2.617366673549016,-8.720731095726567,-9.54920402404825,24.48103049828725,38.33199848017278,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-04,2.684999942779541,2.740000009536743,2.6050000190734863,2.7300000190734863,582010,0.0,0.0,2.888000011444092,3.2598750054836274,2.63428334047397,-5.470913841568874,-11.407645796663456,23.748078097669588,39.84939939906233,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-05,2.740000009536743,2.805000066757202,2.509999990463257,2.5899999141693115,780405,0.0,0.0,2.8475000143051146,3.2573750019073486,2.6500666732589404,-9.043023664343746,-12.582984377366213,22.916718842457122,36.46722033663276,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-06,2.5899999141693115,2.6700000762939453,2.5,2.6649999618530273,457166,0.0,0.0,2.8200000047683718,3.249000000953674,2.6665250062942505,-5.496455413235921,-13.204062667263116,21.843972709219276,39.43293397558993,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-09,2.6649999618530273,2.7699999809265137,2.505000114440918,2.5199999809265137,666651,0.0,0.0,2.7720000028610228,3.240125000476837,2.681775006155173,-9.090909872814432,-14.44774499585424,20.820165488907428,35.939925649043204,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-10,2.515000104904175,2.515000104904175,2.1649999618530273,2.2300000190734863,1745721,0.0,0.0,2.7,3.2127499997615816,2.6944750065604848,-17.40740670098199,-15.95984747644954,19.234730028640286,30.181586130543252,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-11,2.200000047683716,2.319999933242798,2.140000104904175,2.240000009536743,982433,0.0,0.0,2.6384999990463256,3.18575000166893,2.7070250064134598,-15.10327798573502,-17.178058615268448,17.684542777450492,30.594538600077357,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-12,2.2249999046325684,2.380000114440918,2.2100000381469727,2.325000047683716,490668,0.0,0.0,2.5829999923706053,3.14300000667572,2.7206666732827824,-9.988383486215358,-17.817372354937223,15.523156053635425,34.15928661068391,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-13,2.3299999237060547,2.3499999046325684,2.25,2.319999933242798,196418,0.0,0.0,2.515999984741211,3.102250003814697,2.734250006079674,-7.790145178342412,-18.897574932793965,13.458900865567008,34.048502185518885,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-16,2.309999942779541,2.365000009536743,2.2100000381469727,2.3399999141693115,330922,0.0,0.0,2.4649999856948854,3.0745000004768372,2.7477000052730243,-5.070996845881778,-19.824362162544215,11.893583527192249,34.95716694707144,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-17,2.3450000286102295,2.484999895095825,2.2699999809265137,2.4549999237060547,410432,0.0,0.0,2.4414999723434447,3.0363749980926515,2.7624000047643977,0.5529367813038386,-19.591619155173102,9.918005823042304,40.07015909826461,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-18,2.490000009536743,2.690000057220459,2.490000009536743,2.5299999713897705,897867,0.0,0.0,2.4214999675750732,3.009375,2.777716671427091,4.480694002376998,-19.534788201035987,8.339883291764636,43.20581155522436,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-19,2.509999990463257,2.5299999713897705,2.4100000858306885,2.5,324168,0.0,0.0,2.4124999761581423,2.980374997854233,2.7928166712323823,3.6269440292886452,-19.053811084341437,6.715740727051983,42.253473374823635,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-20,2.5,2.5250000953674316,2.319999933242798,2.4049999713897705,350066,0.0,0.0,2.3864999771118165,2.9447499990463255,2.8050333375732106,0.7751935661169804,-18.957467428994022,4.980926950194164,39.29939209566782,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-23,2.375,2.380000114440918,2.299999952316284,2.3399999141693115,331139,0.0,0.0,2.3684999704360963,2.9088749945163728,2.816466670234998,-1.2032956142083984,-18.576770232442346,3.2810018757887387,37.374062785684,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-27,2.3299999237060547,2.494999885559082,2.255000114440918,2.2950000762939453,512549,0.0,0.0,2.374999976158142,2.8749999940395354,2.825058337052663,-3.3684168702016857,-17.391305005843332,1.767809759248221,36.05704624263743,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2024-12-30,2.2699999809265137,2.2699999809265137,2.1600000858306885,2.2200000286102295,386144,0.0,0.0,2.372999978065491,2.8373749971389772,2.8265166699886324,-6.447532695722548,-16.366360440256635,0.3841593175669655,33.912125710180746,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-02,2.2100000381469727,2.5299999713897705,2.1600000858306885,2.4700000286102295,617119,0.0,0.0,2.387499976158142,2.8046249985694884,2.824058336019516,3.4554996136520586,-14.872755631291279,-0.6881351281651936,45.541357429854614,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-03,2.4700000286102295,2.619999885559082,2.444999933242798,2.490000009536743,804515,0.0,0.0,2.4044999837875367,2.7764999985694887,2.823850001891454,3.555833908325836,-13.398163694349513,-1.6767888977902319,46.35462929457403,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-07,2.5,2.7950000762939453,2.5,2.7049999237060547,772424,0.0,0.0,2.440999984741211,2.752374994754791,2.829641668001811,10.815237223069152,-11.312957377064112,-2.730616887670538,54.26211480160193,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-08,2.740000009536743,2.755000114440918,2.4000000953674316,2.4800000190734863,1344887,0.0,0.0,2.4434999942779543,2.7268749952316282,2.8339583347241084,1.4937599705752271,-10.391932209917943,-3.778578470276097,46.531989920165536,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-09,2.4700000286102295,2.490000009536743,2.4000000953674316,2.440000057220459,317538,0.0,0.0,2.434500002861023,2.7046249985694883,2.837583334247271,0.2259213125065707,-9.987521222030342,-4.685618711989399,45.29656324859562,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-10,2.434999942779541,2.4700000286102295,2.3299999237060547,2.359999895095825,467562,0.0,0.0,2.4204999923706056,2.682249993085861,2.8410833328962326,-2.4994876044402483,-9.758598243637937,-5.590590672623985,42.8463965973142,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-13,2.3550000190734863,2.369999885559082,2.25,2.25,554944,0.0,0.0,2.4049999952316283,2.6567499935626984,2.8438833326101305,-6.44490625941561,-9.475863327037167,-6.58020450071277,39.66902515812872,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-14,2.2799999713897705,2.380000114440918,2.25,2.259999990463257,417403,0.0,0.0,2.3970000028610228,2.634499990940094,2.8483666658401487,-5.715478190832073,-9.01499293588237,-7.508396916201557,40.10388006200128,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-15,2.2850000858306885,2.369999885559082,2.240000009536743,2.3499999046325684,231059,0.0,0.0,2.4024999856948854,2.6179999887943266,2.8539499988158545,-2.1852271123794513,-8.231474561567353,-8.267489273443019,44.01501490223078,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-16,2.3499999046325684,2.3499999046325684,2.259999990463257,2.309999942779541,375128,0.0,0.0,2.4114999771118164,2.6041249871253966,2.859799998005231,-4.2090000122595495,-7.39691877179107,-8.940310897901007,42.68105906537126,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-17,2.309999942779541,2.315000057220459,2.234999895095825,2.25,210108,0.0,0.0,2.3894999742507936,2.5887499868869783,2.8623333315054578,-5.838040416574293,-7.696765375005822,-9.558053270985981,40.689037841638445,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-20,2.259999990463257,2.2899999618530273,2.1649999618530273,2.2049999237060547,370911,0.0,0.0,2.3609999656677245,2.5726249873638154,2.8639583309491474,-6.607371631941163,-8.226034604170751,-10.172401617616446,39.210907391276336,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-21,2.2049999237060547,2.25,2.1050000190734863,2.25,399262,0.0,0.0,2.3154999732971193,2.5567499876022337,2.8664583305517835,-2.8287615656437115,-9.435807782338664,-10.804564631153452,41.49955636186583,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-22,2.2149999141693115,2.2149999141693115,2.049999952316284,2.0850000381469727,640338,0.0,0.0,2.275999975204468,2.5269999861717225,2.8650833308696746,-8.391912967412775,-9.932727041582098,-11.800122567301713,36.12851051184688,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-23,2.0799999237060547,2.1549999713897705,2.0299999713897705,2.140000104904175,366695,0.0,0.0,2.245999979972839,2.4974999904632567,2.859166665871938,-4.719495815398281,-10.07007052855953,-12.649373669806224,38.964233880149216,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-24,2.0799999237060547,2.180000066757202,2.0799999237060547,2.1700000762939453,230887,0.0,0.0,2.2269999980926514,2.4768749952316282,2.8567083338896433,-2.559493571958892,-10.088316835529662,-13.29618897918223,40.51555790394338,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-27,2.0999999046325684,2.5450000762939453,2.0199999809265137,2.484999895095825,2337460,0.0,0.0,2.250499987602234,2.4654999911785125,2.8580833335717517,10.419902634322442,-8.720340877937232,-13.735895583654209,53.79503348008055,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-28,2.509999990463257,2.5999999046325684,2.119999885559082,2.180000066757202,1361728,0.0,0.0,2.2424999952316282,2.4449999928474426,2.854000000158946,-2.787064820839407,-8.282208515672968,-14.330764095610549,43.637061626911105,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-29,2.1700000762939453,2.240000009536743,2.0999999046325684,2.174999952316284,293431,0.0,0.0,2.225,2.4256249904632567,2.8462916672229768,-2.2471931543243104,-8.271063798074591,-14.779464859627305,43.49207099450135,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-30,2.1700000762939453,2.184999942779541,2.0899999141693115,2.115000009536743,342096,0.0,0.0,2.20550000667572,2.407124990224838,2.838250001271566,-4.103377776696759,-8.376174248030432,-15.189818051742417,41.70149939895134,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-01-31,2.115000009536743,2.194999933242798,2.059999942779541,2.180000066757202,355202,0.0,0.0,2.1985000133514405,2.3896249890327455,2.8308750013510386,-0.8414803949005512,-7.998115878369144,-15.58705390056806,44.3733495563125,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-03,2.1700000762939453,2.1700000762939453,2.049999952316284,2.069999933242798,333594,0.0,0.0,2.185000014305115,2.366624987125397,2.8168750007947287,-5.263161570224978,-7.6744297811581585,-15.98402533098921,40.95275214365981,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-04,2.049999952316284,2.190000057220459,2.0450000762939453,2.119999885559082,228849,0.0,0.0,2.172000002861023,2.3483749866485595,2.796708333492279,-2.394112211484576,-7.51051194082282,-16.03075091795078,43.09986135798607,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-05,2.119999885559082,2.119999885559082,1.9819999933242798,2.0450000762939453,567752,0.0,0.0,2.16800000667572,2.3322499871253966,2.781833334763845,-5.673428505674936,-7.042554672799975,-16.161404855572137,40.708657993237054,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-06,2.009999990463257,2.049999952316284,1.9880000352859497,2.0199999809265137,232960,0.0,0.0,2.155999994277954,2.3144999861717226,2.7724166671435038,-6.307978372559645,-6.848131036541238,-16.516878086856444,39.91372756978245,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-07,2.0250000953674316,2.0350000858306885,1.9639999866485596,1.9739999771118164,207457,0.0,0.0,2.136399984359741,2.299099987745285,2.760241667429606,-7.601573134096166,-7.076682364958947,-16.706569034360875,38.42684079138851,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-10,1.9800000190734863,2.0,1.7899999618530273,1.812000036239624,764889,0.0,0.0,2.069099998474121,2.27777498960495,2.7488000015417735,-12.425690513948004,-9.161352288226709,-17.135659621384985,33.66979094168923,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-11,1.7899999618530273,1.7999999523162842,1.6660000085830688,1.684000015258789,903707,0.0,0.0,2.01949999332428,2.256874990463257,2.736916669209798,-16.61302199428223,-10.517862005739733,-17.53950656031989,30.46109609816392,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-12,1.690000057220459,1.843999981880188,1.6779999732971191,1.7879999876022339,806728,0.0,0.0,1.9807999968528747,2.2458249896764757,2.72785833577315,-9.733441516405714,-11.800785637432035,-17.67076170251535,35.8133939687246,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-13,1.7740000486373901,1.7999999523162842,1.7000000476837158,1.7380000352859497,236462,0.0,0.0,1.9430999994277953,2.2332749903202056,2.7200083355108897,-10.55529639247818,-12.993249472193533,-17.894553440743874,34.440907503350545,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-14,1.7400000095367432,1.7400000095367432,1.649999976158142,1.6779999732971191,342488,0.0,0.0,1.892899990081787,2.2170999884605407,2.713408335049947,-11.352951445437046,-14.622705338781955,-18.29095680802759,32.81569202574828,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-17,1.659999966621399,1.784000039100647,1.649999976158142,1.75,214213,0.0,0.0,1.8608999967575073,2.202849990129471,2.707366669178009,-5.959481807229999,-15.523072152174363,-18.634959379244915,36.67724340406162,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-18,1.75,2.0350000858306885,1.75,2.0,921233,0.0,0.0,1.8489000082015992,2.194349992275238,2.7038250029087068,8.172426368550553,-15.742702180131928,-18.842750920839496,47.87926775637446,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-19,1.9700000286102295,1.9700000286102295,1.7000000476837158,1.7899999618530273,845698,0.0,0.0,1.8233999967575074,2.1777249932289124,2.6959500034650166,-1.8317448153929068,-16.270419707405175,-19.222352401567033,41.27417200256018,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-20,1.7879999876022339,1.8079999685287476,1.7319999933242798,1.7760000228881836,218728,0.0,0.0,1.7990000009536744,2.1588749945163728,2.6820000032583873,-1.27848682897711,-16.66956143717422,-19.505033859301452,40.869389971269996,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-21,1.75,1.7599999904632568,1.6799999475479126,1.7139999866485596,281687,0.0,0.0,1.7730000019073486,2.1392249941825865,2.669700002670288,-3.327694032448863,-17.11951726775589,-19.870210434022916,39.04322895410623,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-24,1.6720000505447388,1.7200000286102295,1.6419999599456787,1.6959999799728394,179538,0.0,0.0,1.7613999962806701,2.1214999943971633,2.659666668375333,-3.712956537182234,-16.97383922071693,-20.234365470576456,38.50529766795079,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-25,1.6979999542236328,1.781999945640564,1.694000005722046,1.7200000286102295,155471,0.0,0.0,1.7649999976158142,2.1059999972581864,2.6508750011523565,-2.5495733182080023,-16.191832862598392,-20.554534018288624,39.69828243264558,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-26,1.7200000286102295,1.7660000324249268,1.6360000371932983,1.6399999856948853,248674,0.0,0.0,1.7501999974250793,2.0896249949932098,2.6425416668256125,-6.296423945396065,-16.24334502034579,-20.923669010547755,37.11367863442953,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-27,1.6319999694824219,1.690000057220459,1.621999979019165,1.6699999570846558,270595,0.0,0.0,1.74339998960495,2.0758749932050704,2.634124999245008,-4.210165937704657,-16.016137999080186,-21.192996011956268,38.72477847610359,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-02-28,1.6720000505447388,1.6820000410079956,1.621999979019165,1.6419999599456787,158056,0.0,0.0,1.7397999882698059,2.0551749914884567,2.625183332959811,-5.6213374516335755,-15.345408762016955,-21.71308701814315,37.752624094733534,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-03,1.6260000467300415,1.6399999856948853,1.5399999618530273,1.5640000104904175,316935,0.0,0.0,1.7211999893188477,2.0320249915122988,2.6152999997138977,-9.133161736228045,-15.296317884462882,-22.302413041158058,35.108512713979806,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-04,1.5679999589920044,1.7100000381469727,1.406000018119812,1.437999963760376,555003,0.0,0.0,1.6649999856948852,2.0003499925136565,2.605283331871033,-13.633635068157139,-16.76456660453543,-23.219483729738226,31.2954427808413,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-05,1.4320000410079956,1.7000000476837158,1.4320000410079956,1.6399999856948853,600557,0.0,0.0,1.649999988079071,1.9793499916791917,2.5974916646877926,-0.606060754935383,-16.639301032391696,-23.79763836827938,42.14408735466694,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-06,1.6519999504089355,1.684000015258789,1.5119999647140503,1.5640000104904175,380099,0.0,0.0,1.6287999868392944,1.9574499905109406,2.5863999982674915,-3.9783875781225926,-16.789701155321,-24.31758460322669,39.6098907878194,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-07,1.5479999780654907,1.649999976158142,1.5019999742507935,1.6039999723434448,237493,0.0,0.0,1.617799985408783,1.938549992442131,2.5783499985933305,-0.8530110761406153,-16.545872341897983,-24.814319487278876,41.60031195668214,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-10,1.6200000047683716,1.6460000276565552,1.5399999618530273,1.5779999494552612,158819,0.0,0.0,1.6059999823570252,1.9217499911785125,2.5690416653951007,-1.743464085265438,-16.430337466938337,-25.195841816642517,40.6621700090478,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-11,1.5520000457763672,1.5520000457763672,1.4700000286102295,1.5299999713897705,312096,0.0,0.0,1.5869999766349792,1.9034999907016754,2.5597916642824807,-3.591682803050163,-16.627266383648724,-25.638479987970676,38.91728621818641,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-12,1.5299999713897705,1.7300000190734863,1.5299999713897705,1.6979999542236328,395974,0.0,0.0,1.592799973487854,1.887199991941452,2.5514416635036468,6.604720146084373,-15.599831481068138,-26.033974480531775,47.421548227319775,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-13,1.690000057220459,1.690000057220459,1.5740000009536743,1.628000020980835,172577,0.0,0.0,1.588599979877472,1.8701499938964843,2.542758329709371,2.4801738387534127,-15.054942915696238,-26.451917508407636,44.633185528836464,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-14,1.621999979019165,1.6640000343322754,1.590000033378601,1.6119999885559082,116838,0.0,0.0,1.5855999827384948,1.8541999936103821,2.533941662311554,1.6649852487900438,-14.486032348047107,-26.825466379564823,43.996392177368094,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-17,1.6100000143051147,1.656000018119812,1.5499999523162842,1.6239999532699585,230820,0.0,0.0,1.591599977016449,1.8396749943494797,2.525724996129672,2.0356858960406092,-13.484719751857662,-27.162498008748777,44.6343977242371,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-18,1.6139999628067017,1.656000018119812,1.6119999885559082,1.6419999599456787,161670,0.0,0.0,1.6119999766349793,1.8244749933481217,2.5174083282550175,1.861041175281146,-11.645816878159906,-27.525663084908192,45.63487271874172,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-19,1.656000018119812,1.656000018119812,1.6200000047683716,1.6399999856948853,118070,0.0,0.0,1.6119999766349793,1.8133499920368195,2.509199994802475,1.7369732919199834,-11.103759135635842,-27.731946604775636,45.53641235348506,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-20,1.6360000371932983,1.715999960899353,1.6299999952316284,1.7000000476837158,295188,0.0,0.0,1.625599980354309,1.802349990606308,2.5015749951203663,4.57677585067335,-9.806641949299788,-27.951390858878256,49.085510204436794,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-21,1.7100000381469727,1.8739999532699585,1.6759999990463257,1.7799999713897705,653414,0.0,0.0,1.6431999802589417,1.7925999879837036,2.494699994723002,8.32521864498023,-8.334263568349423,-28.143664898562516,53.441925694162684,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-24,1.7999999523162842,2.1500000953674316,1.7999999523162842,2.059999942779541,1349772,0.0,0.0,1.6913999795913697,1.7819749891757966,2.4879916608333588,21.792595934476864,-5.082844042963805,-28.37697098313747,64.7956298498168,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-25,2.059999942779541,2.240000009536743,2.0199999809265137,2.065000057220459,808858,0.0,0.0,1.7448999881744385,1.779099988937378,2.482283327976863,18.34489490603515,-1.922320329132625,-28.328085320244277,64.95995869933037,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-26,2.055000066757202,2.055000066757202,1.9019999504089355,1.9800000190734863,282939,0.0,0.0,1.773099994659424,1.774224990606308,2.4766166607538858,11.668830017328133,-0.06340773875017573,-28.360936162553667,59.84579379639894,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-27,1.9819999933242798,2.1500000953674316,1.9520000219345093,2.005000114440918,252452,0.0,0.0,1.8108000040054322,1.7714749932289124,2.471158327658971,10.724547714044693,2.219902111338362,-28.313982418637547,60.82273917630104,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-28,1.9520000219345093,2.055000066757202,1.8700000047683716,1.9279999732971191,227503,0.0,0.0,1.8424000024795533,1.7651749908924104,2.4653916617234546,4.646112174466079,4.374921012681051,-28.40184307030354,56.28087039381682,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-03-31,1.9279999732971191,1.9279999732971191,1.7920000553131104,1.8020000457763672,136770,0.0,0.0,1.860200011730194,1.7584749937057496,2.45849166115125,-3.128693989185299,5.784843025266606,-28.473420451534103,49.735975107186185,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-01,1.8020000457763672,1.8700000047683716,1.75,1.8700000047683716,138592,0.0,0.0,1.8830000162124634,1.7522249966859818,2.4523249953985213,-0.6903882810495406,7.463369132036071,-28.54841833876786,52.91811163876215,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-02,1.9900000095367432,2.0850000381469727,1.9299999475479126,1.972000002861023,590862,0.0,0.0,1.9162000179290772,1.7503999948501587,2.4469249963760378,2.912012546177264,9.472122004497129,-28.465318820865022,57.286332662870876,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-03,2.005000114440918,2.440000057220459,2.005000114440918,2.075000047683716,1950934,0.0,0.0,1.953700017929077,1.7517749965190887,2.442049996058146,6.208733615266934,11.526881124072947,-28.26621079229623,61.2009863678109,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-04,2.069999933242798,2.1050000190734863,1.8680000305175781,1.9579999446868896,504469,0.0,0.0,1.9715000152587892,1.7513749957084657,2.4359499951203665,-0.684761372934984,12.568697171634483,-28.102998862177962,55.03121457423318,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-07,1.9500000476837158,1.9500000476837158,1.6720000505447388,1.850000023841858,439844,0.0,0.0,1.9505000233650207,1.7523249953985214,2.4263666619857154,-5.1525249074224195,11.309262179498244,-27.77987668341786,50.01860236139873,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-08,1.850000023841858,1.9459999799728394,1.812000036239624,1.8569999933242798,291534,0.0,0.0,1.9297000169754028,1.7566499948501586,2.417883328596751,-3.76742618083574,9.851138395956067,-27.347611273301077,50.33437052892642,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-09,1.8489999771118164,1.8569999933242798,1.7419999837875366,1.7999999523162842,240691,0.0,0.0,1.9117000102996826,1.75694999396801,2.405174994468689,-5.842969994329187,8.807878247130708,-26.951261425527743,47.69214138685666,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-10,1.840000033378601,1.8600000143051147,1.7419999837875366,1.7690000534057617,242559,0.0,0.0,1.888100004196167,1.7577249944210052,2.392249995470047,-6.307925985155142,7.4172586831825456,-26.524192799689633,46.26957945865407,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-11,1.7899999618530273,1.8200000524520874,1.7339999675750732,1.7799999713897705,104837,0.0,0.0,1.8733000040054322,1.7602749943733216,2.3734583298365277,-4.980517397969915,6.420872306508496,-25.835015839753094,46.87511027944463,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-14,1.777999997138977,1.8170000314712524,1.7410000562667847,1.7690000534057617,96830,0.0,0.0,1.8700000047683716,1.7607499957084656,2.355283329884211,-5.401066904014274,6.204742826987629,-25.24253989455161,46.31302291109244,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-15,1.7699999809265137,1.7990000247955322,1.7549999952316284,1.7890000343322754,133841,0.0,0.0,1.861900007724762,1.7554749965667724,2.3414416631062824,-3.915353836942634,6.062462374350405,-25.025892200198363,47.54464140398577,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-16,1.7890000343322754,1.8969999551773071,1.7890000343322754,1.809999942779541,103096,0.0,0.0,1.8457000017166139,1.7559749960899353,2.3233583291371662,-1.9342286885121962,5.109697223848345,-24.42082764125076,48.8709586098606,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-17,1.7999999523162842,1.7999999523162842,1.7430000305175781,1.7760000228881836,79018,0.0,0.0,1.8157999992370606,1.7559749960899353,2.3080749968687693,-2.191870049873314,3.406939351661543,-23.92036660541082,46.80739804814718,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-22,1.7510000467300415,1.7680000066757202,1.715999960899353,1.7400000095367432,48652,0.0,0.0,1.794000005722046,1.75662499666214,2.2920749962329863,-3.0100332225790045,2.127660094267383,-23.360928436061464,44.65725272012009,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-23,1.7280000448226929,1.8799999952316284,1.659999966621399,1.8600000143051147,358837,0.0,0.0,1.7950000047683716,1.7607249975204469,2.275658330321312,3.621170438109875,1.9466417127145226,-22.627884245178365,52.491355098685396,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-24,1.8799999952316284,1.8799999952316284,1.809000015258789,1.8580000400543213,113676,0.0,0.0,1.7951000094413758,1.764174997806549,2.2596833298603696,3.5039847519425718,1.7529446723412774,-21.92822000790876,52.358327388014345,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-25,1.8539999723434448,1.9299999475479126,1.8539999723434448,1.8990000486373901,83865,0.0,0.0,1.8050000190734863,1.7706499993801117,2.2450916628042856,5.207757815545866,1.939966662265282,-21.132396119255155,54.882635055307574,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-28,1.9240000247955322,2.2939999103546143,1.909000039100647,1.9900000095367432,952110,0.0,0.0,1.8271000146865846,1.7786500006914139,2.230633330345154,8.915767803663556,2.7239768350342524,-20.262556086876145,59.95432656120442,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-29,2.0,2.196000099182129,1.8079999685287476,1.8860000371932983,491047,0.0,0.0,1.8377000212669372,1.7847500026226044,2.2148499975601834,2.6282861929262205,2.9668031134066557,-19.418922067470263,52.66764629056577,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-04-30,1.8849999904632568,1.8849999904632568,1.8200000524520874,1.850000023841858,115887,0.0,0.0,1.845800018310547,1.7919000029563903,2.200141664346059,0.22754390993858553,3.007981207948491,-18.555244328369604,50.384869521649065,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-02,1.8700000047683716,1.9049999713897705,1.7719999551773071,1.8899999856948853,431431,0.0,0.0,1.8559000134468078,1.803200003504753,2.1853083302577336,1.8373819710656965,2.9225826219845494,-17.48532788084485,52.83120446747246,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-05,1.8600000143051147,1.8600000143051147,1.7879999876022339,1.8359999656677246,114918,0.0,0.0,1.8585000157356262,1.8081000030040741,2.171441663304965,-1.210656436771439,2.787457145501618,-16.73273873486795,49.29738247765434,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-06,1.819000005722046,1.8320000171661377,1.7910000085830688,1.819000005722046,218361,0.0,0.0,1.8628000140190124,1.8144750028848649,2.1588499973217647,-2.3512995473125153,2.6633054220815824,-15.951779644909378,48.20423683251308,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-07,1.8179999589920044,1.8179999589920044,1.7489999532699585,1.7740000486373901,98575,0.0,0.0,1.8662000179290772,1.8187250047922134,2.146508330106735,-4.940519151532395,2.6103458748172708,-15.27053590787708,45.338289626343844,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-08,1.7649999856948853,1.8589999675750732,1.7170000076293945,1.819000005722046,232710,0.0,0.0,1.8621000170707702,1.824750006198883,2.134416663646698,-2.314591641351469,2.0468563225102034,-14.508257114088613,48.62754774287837,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-09,1.9579999446868896,1.9579999446868896,1.8389999866485596,1.8580000400543213,208425,0.0,0.0,1.8621000170707702,1.8329500079154968,2.123649996519089,-0.22018027919351596,1.5903330166884353,-13.688695834063216,51.35936442368541,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-12,1.8539999723434448,1.8539999723434448,1.6119999885559082,1.6260000467300415,1012938,0.0,0.0,1.8348000168800354,1.831150010228157,2.1121166636546453,-11.379985187979527,0.19932865311365344,-13.302610516803796,38.30884090418565,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-13,1.6260000467300415,1.6260000467300415,1.3769999742507935,1.399999976158142,1552397,0.0,0.0,1.7758000135421752,1.8254500091075898,2.099908330043157,-21.16229499483039,-2.7198770340299303,-13.070014391053276,30.246096211683977,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-14,1.3990000486373901,1.468999981880188,1.3509999513626099,1.4210000038146973,553462,0.0,0.0,1.7293000102043152,1.8206750094890594,2.0878749966621397,-17.82802316373043,-5.0187429831525465,-12.797700417900963,31.684883800317365,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-15,1.430999994277954,1.4670000076293945,1.3899999856948853,1.4320000410079956,259761,0.0,0.0,1.687500011920929,1.8158750116825104,2.076058331131935,-15.140738910104687,-7.069594489470663,-12.532563057010258,32.4706256076129,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-16,1.465999960899353,1.465999960899353,1.4160000085830688,1.440000057220459,134478,0.0,0.0,1.6425000190734864,1.8108250141143798,2.0640166650215783,-12.328764657625703,-9.295486517410193,-12.266938305197819,33.07352163226189,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-19,1.437999963760376,1.5,1.3899999856948853,1.3990000486373901,422834,0.0,0.0,1.5988000273704528,1.8048000156879425,2.048383331298828,-12.496871110371057,-11.4140063456819,-11.891490810776894,31.520353274743,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-20,1.3990000486373901,1.399999976158142,1.2100000381469727,1.2630000114440918,1023961,0.0,0.0,1.5432000279426574,1.793875014781952,2.0312416652838388,-18.15707694563218,-13.973938249525396,-11.685790743600071,26.992244458587223,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-21,1.284000039100647,1.2869999408721924,1.1990000009536743,1.2000000476837158,477974,0.0,0.0,1.48580002784729,1.7793750166893005,2.016283333301544,-19.235427029682935,-16.49876985393642,-11.749753256369994,25.18718556459224,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-22,1.2000000476837158,1.2690000534057617,1.1670000553131104,1.1990000009536743,353956,0.0,0.0,1.423800027370453,1.7578500181436538,2.001774999499321,-15.788735924661475,-19.00332720797013,-12.185434497717122,25.158424795094504,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-23,1.1740000247955322,1.2039999961853027,1.1299999952316284,1.1469999551773071,457495,0.0,0.0,1.3527000188827514,1.7349000155925751,1.986333332459132,-15.206628286686955,-22.030087801877094,-12.65816329806417,23.646416055259934,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-26,1.1399999856948853,1.1460000276565552,1.0399999618530273,1.1009999513626099,1038854,0.0,0.0,1.3002000093460082,1.7129250138998031,1.9709249983231227,-15.320724238695755,-24.094750278305945,-13.090299460549126,22.365869234609107,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-27,1.2000000476837158,1.2000000476837158,1.090000033378601,1.149999976158142,645498,0.0,0.0,1.2752000093460083,1.6915500104427337,1.9567166646321614,-9.818070284682289,-24.613520057131094,-13.55161219722508,26.90665574624485,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-28,1.149999976158142,1.1770000457763672,1.1139999628067017,1.1139999628067017,211793,0.0,0.0,1.2445000052452087,1.6712000101804734,1.9419999967018764,-10.486142377540132,-25.532551599804336,-13.944386559284558,25.71655893721936,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-05-30,1.1339999437332153,1.1339999437332153,1.0299999713897705,1.0399999618530273,1090986,0.0,0.0,1.2052999973297118,1.6521500080823899,1.925749996304512,-13.71443091702475,-27.04657619263798,-14.207451057881693,23.423149449900436,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-02,1.1649999618530273,1.7380000352859497,1.152999997138977,1.1890000104904175,8212215,0.0,0.0,1.1801999926567077,1.635125008225441,1.9119083305199942,0.7456378485395804,-27.822032766929034,-14.476809263092374,35.831881866068656,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-03,1.2300000190734863,1.2619999647140503,1.121000051498413,1.1629999876022339,1281647,0.0,0.0,1.1565999865531922,1.6149000078439713,1.8991833299398422,0.5533461113132536,-28.37946740136862,-14.968714057998591,34.77300811117493,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-04,1.0281319618225098,1.0483429431915283,0.9885879755020142,1.0193439722061157,1019431,0.0,0.0,1.1322343826293946,1.5885086059570312,1.884927862882614,-9.970586669618068,-28.72343414549803,-15.725761328195858,29.572992892883647,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-05,1.036041021347046,1.036041021347046,0.9727709889411926,1.0105570554733276,1447475,0.0,0.0,1.1132900834083557,1.564822533726692,1.8717658390601477,-9.227875956687695,-28.855185849285576,-16.398595322563327,29.284524715365464,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-09,1.0000120401382446,1.0105570554733276,0.982437014579773,1.0052850246429443,530122,0.0,0.0,1.0939185857772826,1.5437046587467194,1.8579348812500636,-8.102391008500858,-29.136795721961644,-16.912875993367564,29.10110826923342,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-10,1.0061630010604858,1.0061630010604858,0.9428939819335938,0.9622259736061096,1248579,0.0,0.0,1.075441187620163,1.521335308253765,1.8449534311890603,-10.527327325503189,-29.309391441483918,-17.54072040326381,27.58164085781064,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-11,0.9666200280189514,1.0193439722061157,0.9384999871253967,0.9921029806137085,1479595,0.0,0.0,1.0645514905452729,1.5011378839612006,1.8346376225352288,-6.805543045593369,-29.08369697951158,-18.17796247485513,30.3009949280964,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-12,1.0105570554733276,1.0193439722061157,0.9297119975090027,1.0088000297546387,1160881,0.0,0.0,1.0504314959049226,1.4821328833699225,1.8243776227037112,-3.9632728371705337,-29.12703660439956,-18.759533940488975,31.84136572750093,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-13,1.062000036239624,1.128999948501587,1.003000020980835,1.0449999570846558,573982,0.0,0.0,1.043531495332718,1.4637578830122948,1.8137109552820523,0.14072040551776732,-28.708736093347976,-19.294864556592803,35.1857916137898,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-16,1.0449999570846558,1.0950000286102295,1.0019999742507935,1.0299999713897705,490638,0.0,0.0,1.0425314962863923,1.445282880961895,1.8029609555999437,-1.2020284222836828,-27.866612825819615,-19.83837051640587,34.43186500214941,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-17,1.031000018119812,1.2790000438690186,1.031000018119812,1.13100004196167,3056995,0.0,0.0,1.0367314994335175,1.4288328811526299,1.79288595666488,9.092859875451058,-27.442074359515495,-20.305422894240323,43.24940927642714,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-18,1.1440000534057617,1.1510000228881836,1.003999948501587,1.0199999809265137,2689699,0.0,0.0,1.0224314987659455,1.4090828821063042,1.780927623808384,-0.2378171879843926,-27.43993190538162,-20.879273067083822,37.31090793079946,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-19,1.0210000276565552,1.0809999704360962,0.9559999704360962,0.9804999828338623,823449,0.0,0.0,1.01854709982872,1.3891953811049462,1.7680151239037514,-3.7354303007937273,-26.680788485016254,-21.426272755086888,35.44573458387461,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-23,0.972000002861023,0.972000002861023,0.8945000171661377,0.9144999980926514,964845,0.0,0.0,1.0089413940906524,1.3685578808188439,1.754802623887857,-9.360444179527397,-26.27703890119894,-22.01072290473715,32.52042990725232,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-24,0.8949999809265137,0.9100000262260437,0.8715000152587891,0.9045000076293945,706314,0.0,0.0,0.9988628923892975,1.3446703806519509,1.742298457523187,-9.447030766573507,-25.716896366453156,-22.822041490899064,32.08831969118276,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-25,0.9089999794960022,0.9089999794960022,0.8715000152587891,0.8774999976158142,441066,0.0,0.0,0.990390294790268,1.320157879590988,1.7301109582185745,-11.398566582112984,-24.979405107432214,-23.695189992305384,30.894686011192945,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-26,0.8999999761581421,0.9024999737739563,0.8679999709129333,0.8794999718666077,543761,0.0,0.0,0.9791299939155579,1.2946703776717186,1.7183151240150134,-10.175362073275688,-24.372256382633502,-24.654659696727048,31.099139204831374,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
2025-06-27,0.8889999985694885,0.9049999713897705,0.8709999918937683,0.8794999718666077,697719,0.0,0.0,0.9661999881267548,1.2669078767299653,1.7071442902088165,-8.973299247109184,-23.735576526635235,-25.787885417992516,31.099139204831374,,,0.0,0.0,-0.54912,,2.2097988,-17.589998,Isofol Medical AB (publ),Healthcare,"Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden."
